1   **Full title: Automated, miniaturized, and scalable screening of healthcare workers, first**
2   **responders, and students for SARS-CoV-2 in San Diego County**
3
4   **Short title: High-throughput screening for SARS-CoV-2**
5

6   **Authors:**
7   Sydney C Morgan[1,13,¶], Stefan Aigner[1,4,31,¶], Catelyn Anderson[14,¶], Pedro Belda-Ferre[3,31,¶], Peter
8   De Hoff[1,13,31,¶], Clarisse A Marotz[3,31,¶], Shashank Sathe[1,4,31,¶], Mark Zeller[14,¶], Noorsher Ahmed[1,4],
9   Xaver Audhya[21], Nathan A Baer[31], Tom Barber[31], Bethany Barrick[18], Lakshmi Batachari[9],
10 Maryann Betty[2,3,31], Steven M Blue[1,4], Brent Brainard[7], Tyler Buckley[27], Jamie Case[18], Anelizze
11 Castro-Martinez[31], Marisol Chacón[31], Willi Cheung[1,5,31], LaVonnye Chong[2], Nicole G
12 Coufal[1,2,3,30], Evelyn S Crescini[31], Scott DeGrand[2], David P Dimmock[30], J Joelle Donofrio-
13 Odmann[2,3,6,7], Emily R Eisner[31], Mehrbod Estaki[3], Lizbeth Franco Vargas[31], Michele Freddock[30],
14 Robert M Gallant[21,22,24,25], Andrea Galmozzi[10], Nina J Gao[3], Sheldon Gilmer[2], Edyta M Grzelak[29],
15 Abbas Hakim[31], Jonathan Hart[10], Charlotte Hobbs[30], Greg Humphrey[3,31], Nadja Ilkenhans[22,26],
16 Marni Jacobs[13], Christopher A Kahn[6,7], Bhavika K Kapadia[31], Matthew Kim[1,13], Sunil Kurian[18],
17 Alma L Lastrella[31], Elijah S Lawrence[31], Kari Lee[1,4], Qishan Liang[1,4], Hanna Liliom[27], Valentina
18 Lo Sardo[27], Robert Logan[7], Michal Machnicki[31], Celestine G Magallanes[1,13], Clarence K
19 Mah[1,4,8,34], Denise Malacki[2], Ryan J Marina[1,4], Christopher Marsh[18], Natasha K Martin[33],
20 Nathaniel L Matteson[14], Daniel J Maunder[31], Kyle McBride[2], Bryan McDonald[22], Michelle
21 McGraw[14], Audra R Meadows[32], Michelle Meyer[18], Amber L Morey[1,4,5], Jasmine R Mueller[1,4],
22 Toan T Ngo[31], Julie Nguyen[14], Viet Nguyen[14], Laura J Nicholson[10,11], Alhakam Nouri[31], Victoria
23 Nudell[27], Eugenio Nunez[31], Kyle O'Neill[7], R Tyler Ostrander[31], Priyadarshini Pantham[1,13],
24 Samuel S Park[1,4], David Picone[7], Ashley Plascencia[31], Isaraphorn Pratumchai[14], Michael
25 Quigley[19], Michelle Franc Ragsac[4,34], Andrew C Richardson[2], Refugio Robles-Sikisaka[14],
26 Christopher A Ruiz[31], Justin Ryan[2], Lisa Sacco[2], Sharada Saraf[14], Phoebe Seaver[31], Leigh
27 Sewall[23], Elizabeth W Smoot[31], Kathleen M Sweeney[2], Chandana Tekkatte[1,13], Rebecca Tsai[31],
28 Holly Valentine[1,13], Shawn Walsh[23], August Williams[28], Min Yi Wu[31], Bing Xia[31], Brian Yee[1,4],
29 Jason Z Zhang[12], Kristian G Andersen[14,15*], Lauge Farnaes[3, 30*], Rob Knight[3,16,17*], Gene W
30 Yeo[1,4*], Louise C Laurent[1,13*]
31
32 ¶ These authors contributed equally to this work.
33 *Senior authors.
34
35

36 **Affiliations:**
37 [1]Sanford Consortium of Regenerative Medicine, University of California San Diego, La Jolla, CA
38 [2]Rady Children's Hospital, San Diego, CA
39 [3]Department of Pediatrics, University of California San Diego, La Jolla, CA
40 [4]Dept of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA
41 [5]San Diego State University, San Diego, CA
42 [6]Department of Emergency Medicine, University of California San Diego, San Diego, CA
43 [7]San Diego Fire-Rescue Department

[8]Division of Medical Genetics, Department of Medicine, University of California San Diego, La Jolla, CA

[9]Department of Medicine, University of California San Diego, La Jolla, CA

[10]Department of Molecular Medicine, Scripps Research, La Jolla, CA

[11]Department of Medicine, Scripps Clinic, La Jolla, CA

[12]Department of Bioengineering, University of California San Diego, La Jolla, CA

[13]Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Diego, USA

[14]Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA

[15]Scripps Research Translational Institute, La Jolla, CA, USA

[16]Department of Computer Science and Engineering, University of California San Diego, La Jolla, CA, USA

[17]Department of BioEngineering, University of California San Diego, La Jolla, CA, USA

[18]Scripps Clinic Bio-Repository and Bio-Informatics Core, Scripps Clinic, La Jolla, CA

[19]Department of Pathology, Scripps Clinic, La Jolla, CA

[20]University of California San Diego School of Medicine

[21]Division of Biological Sciences, University of California San Diego, La Jolla, CA

[22]NOMIS Center for Immunobiology and Microbial Pathogenesis, Salk Institute for Biological Studies, La Jolla, CA

[23]Departments of Integrative Structural and Computational Biology and Chemistry, The Scripps Research Institute, La Jolla, CA, USA

[24]Molecular and Systems Physiology Lab, Salk Institute for Biological Studies, La Jolla, CA, USA

[25]Gene Expression Lab, Salk Institute for Biological Studies, La Jolla, CA, USA

[26]Ruperto Carola University, Heidelberg, Germany

[27]Department of Neuroscience and Dorris Neuroscience Center, Scripps Research, La Jolla, CA

[28]Department of Dermatology, University of California San Diego, La Jolla, CA

[29]Department of Chemistry, Scripps Research, La Jolla, CA

[30]Rady Children's Institute for Genomic Medicine

[31]Expedited COVID Identification Environment (EXCITE) Laboratory, Department of Pediatrics, University of California San Diego, La Jolla, CA

[32]Perinatal neonatal quality improvement network of Massachusetts, March of Dimes Foundation, Westborough, MA

[33]Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA

[34]Bioinformatics & Systems Biology Program, University of California San Diego, La Jolla, CA

Abstract

Background: Successful containment strategies for SARS-CoV-2, the causative virus of the COVID-19 pandemic, have involved widespread population testing that identifies infections early and enables rapid contact tracing. In this study, we developed a rapid and inexpensive RT-qPCR testing pipeline for population-level SARS-CoV-2 detection, and used this pipeline to establish a clinical laboratory dedicated to COVID-19 testing at the University of California San Diego (UCSD) with a processing capacity of 6,000 samples per day and next-day result turnaround times.

Methods and findings: Using this pipeline, we screened 6,786 healthcare workers and first responders, and 21,220 students, faculty, and staff from UCSD. Additionally, we screened 6,031 preschool-grade 12 students and staff from public and private schools across San Diego County that remained fully or partially open for in-person teaching during the pandemic. Between April 17, 2020 and February 5, 2021, participants provided 161,582 nasal swabs that were tested for the presence of SARS-CoV-2. Overall, 752 positive tests were obtained, yielding a test positivity rate of 0.47%. While the presence of symptoms was significantly correlated with higher viral load, most of the COVID-19 positive participants who participated in symptom surveys were asymptomatic at the time of testing. The positivity rate among preschool-grade 12 schools that remained open for in-person teaching was similar to the positivity rate at UCSD and lower than that of San Diego County, with the children in private schools being less likely to test positive than the adults at these schools.

Conclusions: Most schools across the United States have been closed for in-person learning for much of the 2020-2021 school year, and their safe reopening is a national priority. However, as there are no vaccines against SARS-CoV-2 currently available to the majority of school-aged children, the traditional strategies of mandatory masking, physical distancing, and repeated viral testing of students and staff remain key components of risk mitigation in these settings. The

113   data presented here suggest that the safety measures and repeated testing actions taken by

114   participating healthcare and educational facilities were effective in preventing outbreaks, and

115   that a similar combination of risk-mitigation strategies and repeated testing may be successfully

116   adopted by other healthcare and educational systems.

117

118   **Key words:** SARS-CoV-2; COVID-19; viral load; symptoms; testing; population; age; sex;

119   demographics

120

Introduction

122   Coronavirus Disease 2019 (COVID-19) is a serious respiratory illness caused by the

123   Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The COVID-19 pandemic

124   has had a dramatic and negative impact on the health, well-being, and productivity of

125   communities around the world, with over 165 million confirmed cases and 3.4 million deaths

126   worldwide, including more than 33 million confirmed cases and 587,000 deaths in the United

127   States (US) alone, within the 18 months since this virus was discovered (1).

128   Given the lack of widely available and highly effective preventative or therapeutic agents

129   besides the recent ramp-up of vaccine availability, social interventions such as "stay-at-home"

130   orders, temporary school and business closures, and mask-wearing/physical distancing

131   measures have been enacted in much of the world to slow the spread of the SARS-CoV-2 virus.

132   While many of these measures are effective at slowing viral spread through a community when

133   carried out correctly (2–4), they do not completely halt the spread of the virus, nor are they

134   sustainable long term. Indeed, a major concern in the US and other similarly affected countries

135   is how to safely reopen schools. Some schools and universities in the US have partially

136   reopened, using a hybrid of online and in-person teaching, or have fully reopened with

137   increased safety measures in place. The CDC has recently issued recommendations on how to

138   limit the spread of COVID-19 in schools (https://www.cdc.gov/coronavirus/2019-

139   ncov/community/schools-childcare/operation-strategy.html), which include universal and correct

140   use of masks, physical distancing, handwashing, and contact tracing, but, so far, few studies

141   have investigated how these measures may work in practice in this environment (5–8).

142   The countries that have demonstrated the greatest success in controlling the COVID-19

143   pandemic, including New Zealand, Australia, and South Korea, have combined risk-mitigating

144   strategies with large-scale and widespread testing, as well as aggressive contact tracing, to

145   both identify outbreaks and curb community transmission. Importantly, this broad testing must

146   be implemented with a minimal turnaround time to allow for effective contact tracing and

147   isolation of affected persons. Even now, nearly 1.5 years after the initial reports of COVID-19

148   infections, it can be difficult for many people in the US and other countries to obtain a test for

149   SARS-CoV-2 if they do not exhibit symptoms or have not been in known contact with a person

150   with a confirmed case of COVID-19. In the context of overall limited testing capacity, these

151   measures are intended to allow medical doctors to triage patients into appropriate treatment

152   pipelines. However, in the context of a pandemic, these measures exclude key demographics,

153   namely asymptomatic and pre-symptomatic carriers, who contribute to the "silent spread" of the

154   virus (9,10). Therefore, the current symptom- and contact-based testing strategies employed in

155   much of the world are both unlikely to accurately capture the full extent to which this novel

156   coronavirus can spread throughout our communities.

157   Some regions have screened large, representative proportions of their target populations

158   with great success, and provide an insight into the proportion of COVID-19 cases that may be

159   missed with current testing restrictions. These studies, which estimate that the rate of

160   asymptomatic COVID-19 infection may be as high as 40-45%, highlight the importance of

161   routine asymptomatic testing (11–13). Additionally, we now know that asymptomatic and pre-

162   symptomatic infections are transmissible (14,15).

163   The objective of this study was to develop and establish an accurate, high-throughput,

164   rapid, and inexpensive SARS-CoV-2 screening pipeline for use at the population level. To this

165   end, we performed SARS-CoV-2 screening on over 5,000 healthcare workers from two large

166   healthcare systems in San Diego County and 1,162 first responders from San Diego Fire and

167   Rescue. Additionally, we screened 21,220 students, faculty, and staff from the University of

168   California, San Diego (UCSD), and 6,031 students and staff from preschool-grade 12 schools

169   across San Diego County that had remained fully or partially open for in-person teaching

170   throughout the COVID-19 pandemic (4,750 from 11 private schools and 1,281 from 13 public

171   schools). We developed a RT-qPCR testing pipeline that included the miniaturization of a

172   testing kit that was granted Emergency Use Authorization by the U.S. Food and Drug

173   Administration. This pipeline was then used to establish a Clinical Laboratory Improvement

174   Amendments (CLIA) certified laboratory at UCSD, and further refinements were made to

175   increase throughput capacity to 6,000 samples per day with next-day results, and to enable

176   accurate detection from self-collected anterior-nares swab samples. A secondary objective of

177   this study was to identify asymptomatic and pre-symptomatic infections, and to evaluate the

178   effectiveness of health and safety measures implemented by healthcare and educational

179   facilities in response to the COVID-19 pandemic, particularly those developed at educational

180   facilities to safely re-open schools for in-person learning.

181

Methods

SEARCH Study

184   The SEARCH study (San Diego Epidemiology and Research Study for COVID-19

185   Health) was a multi-site study whose aim was to evaluate the presence of COVID-19 infection in

186   potentially exposed healthcare worker and first responder populations in San Diego County (SD

187   County). In particular, employees from Rady Children's Hospital San Diego (RCHSD), Rady

6

188   Children's Institute for Genomic Medicine (RCIGM), Scripps Health, and the San Diego Fire-

189   Rescue Department (SDFD) were screened, along with a small number of employees from

190   other institutions who heard of the study by word of mouth and were allowed to participate.

191   These other institutions included the University of California, San Diego (UCSD), Children's

192   Primary Care Medical Group, Rady Children's Specialists of San Diego, and Sharp HealthCare.

193   Screening took place from April 17 through June 30, 2020. Nasopharyngeal (NP) swabs were

194   obtained from study participants by trained healthcare workers, and RT-qPCR testing was

195   performed in collaborating basic science labs at UCSD and Scripps Research to test for the

196   presence of SARS-CoV-2 in the samples. Participant samples that tested positive using the

197   research lab screening protocol were subjected to confirmatory clinical tests, at which point the

198   positive results were reported to both the survey participant and the SD County Department of

199   Public Health. The members of the research team had final responsibility for the survey design,

200   clinical protocol, and trial oversight. The UCSD Institutional Review Boards (IRB) provided

201   human subject protection oversight of the SEARCH study (IRB approval #200470).

202   **Nasopharyngeal swab production**

203   Due to a shortage of NP swabs when the SEARCH study began, 3D-printed swabs were

204   designed and printed for testing. The swab shafts were 3D-printed in nylon, utilizing material

205   extrusion (i.e. fused filament fabrication) on an Onyx One Professional Desktop 3D Printer

206   (Markforged, Watertown, MA, USA). The nylon swab tips were wrapped with rayon fibers and

207   steam-sterilized. While rayon fibers have previously been found to be slightly inferior to flocked

208   nylon (16), they were readily available and more easily manufactured in this setting.

209   We validated the performance of these 3D-printed swabs in parallel with commercially

210   available NP swabs (FLOQSwab, Copan Diagnostics Inc., Murrieta, CA, USA), using both a

211   commercially available standard viral respiratory panel in pediatric patients, as well as SARS-

212   CoV-2 testing in known positive adult patients. The detailed protocol and complete validation

213   information has been made available on protocols.io (17). Briefly, at Rady Children's Hospital

214   San Diego (RCHSD, CA, USA), 25 pediatric patients were swabbed by respiratory therapists

215   using both the 3D-printed swabs and the commercially-sourced swabs, of which 22 samples

216   were run on the ePlex Respiratory Pathogen (RP) Panel (GenMark Dx, Carlsbad, CA, USA),

217   which test for viruses including adenovirus, human metapneumovirus, respiratory syncytial virus

218   (RSV), and variants of influenza and parainfluenza. The remaining three samples, two negative

219   and one positive for SARS-CoV-2, were analyzed using the Simplexa COVID-19 Direct Kit

220   (DiaSorin Molecular, Cypress, CA, USA). Finally, nine adult outpatients who had previously

221   tested positive for SARS-CoV-2 using various FDA-approved tests performed self-swabs 3 to 14

222   days later, some patients with paired parallel commercial and 3D printed swabs ($n = 4$) and

223   others with the 3D-printed swabs alone ($n = 5$). Results from the 3D-printed swab validation are

224   presented in Table S1.

Sample collection and population screening

226   Inclusion criteria for this study included: (1) Individuals 18 years of age or older with

227   possible exposure to COVID-19 in a work setting. Exclusion criteria included: (1) individuals

228   from whom it was not possible to obtain an adequate nasopharyngeal swab; (2) individuals who

229   needed immediate medical intervention.

230   In an effort to include healthcare workers throughout SD County, multiple study sites at

231   hospitals and clinics were set up; each study site was staffed by individuals from that hosting

232   location. A fixed testing location was set up at RCHSD and a mobile testing unit was created to

233   serve nine Scripps Health locations (Scripps Green Hospital; Scripps Memorial La Jolla

234   Hospital; Scripps Memorial Encinitas Hospital; Scripps Mercy San Diego Hospital; Scripps

235   Mercy Chula Vista Hospital; Scripps Clinic Rancho Bernardo; Scripps Coastal Vista Center;

236   Scripps Clinic Mission Valley; and Scripps Campus Point).

237   Potential healthcare worker participants were informed of the study through an

238   organizational all-user email communication as well as a flyer that was sent to Rady and

239   Scripps Health employees and which contained a QR code that allowed them to fill out an

240   electronic consent form and symptom questionnaire prior to arrival at a study site using

241   REDCap (Research Electronic Data Capture) software hosted at RCHSD. REDCap is a secure,

242   web-based software platform designed to support data capture for research studies (18,19).

243   Paper versions of these forms were also available at the study site if an eligible participant was

244   not able to complete them electronically. Potential firefighter and lifeguard participants were

245   informed of the study through an assignment that was posted to every SDFD worker on their

246   Target Solutions (Vector Solutions, Tampa, FL, USA) accounts. Target Solutions is an online

247   training management system which requires assignments to be opened, read, and confirmed

248   prior to the assignment deadline, to ensure all personnel receive and acknowledge their

249   contents. The assignment contained the details of the study as well as instructions on how to

250   participate. In this way, all firefighters and lifeguards in the SDFD were informed of this study.

251   Potential participants were then asked to complete a three-question quiz: (1) Is

252   participation in this study voluntary? (Answer: yes); (2) Will participants be told about their study

253   findings? (Answer: not necessarily); (3) Is participating in this study the same as receiving a

254   clinical test? (Answer: no). Those who answered any questions incorrectly were re-educated by

255   study staff prior to final enrollment and the collection of samples. The Enrollment Screening

256   Form - completed either electronically using a secure REDCap survey, or using a paper version

257   - collected identifiable information including name, address, contact phone number, date of

258   birth, workplace information, and date and site of testing, in addition to information regarding

259   comorbidities and any active symptoms on the day of testing. A barcode was entered into an

260   electronic data capture file for each participant with matching labels placed on a participant

261   information sheet as well as on the NP swab collection tube, in order to link each sample with

262   the participant. A barcode-associated "synthetic name" was also generated, and was cross-

263   checked with each participant at registration and again at the swabbing station to prevent

264   sample mix-up. Protected health information (PHI) was not provided to the research testing

265   laboratories. Instead, names and identifiable information were stored on REDCap at RCHSD, as

266   specified in the IRB protocol (IRB approval #200470).

267   An NP swab sample was collected from each participant by sampling the posterior

268   nasopharynx through both nares, according to instructions for NP swab collection from the CDC

269   (https://www.cdc.gov/flu/pdf/professionals/flu-specimen-collection-poster.pdf). A qualified team

270   member with appropriate personal protective equipment (PPE), consisting of gown, gloves, N95

271   respirator, and face shield, obtained the sample and placed the NP swab into the barcode-

272   labeled collection tube containing 3 mL viral transport medium (VTM), which was prepared

273   according to CDC guidelines (https://www.cdc.gov/coronavirus/2019-ncov/downloads/Viral-

274   Transport-Medium.pdf). At the end of each sampling day, samples were transported on wet ice

275   in a cooler to a Biosafety Laboratory 2 Plus (BSL-2+) laboratory at Scripps Research (La Jolla,

276   CA, USA) for sample accessioning and plating, as described in the Sample processing, RNA

277   extraction, and RT-qPCR section below.

278   At RCHSD, NP sample collection of healthcare workers and firefighters for this study

279   involved 192 screening hours over 33 sampling days, between April 17 and June 30, 2020, with

280   two registered nurses (RNs) involved in consenting participants for the study, two respiratory

281   therapists involved in swabbing participants, and two additional RNs acting as support staff

282   involved in participant information data entry and specimen handling support, for a total of six

283   healthcare workers at each screening site on each day. Across all the Scripps Health locations,

284   NP sample collection for this study involved 76 screening hours over 20 sampling days,

285   between April 24 and June 30, 2020. The mobile sample collection team increased from six to

286   ten staff (four additional support staff for data entry and specimen handling) for locations with

287   high demand. For the SDFD employees, NP samples were collected at the permanent sampling

288   location at RCHSD between June 1 and June 30, 2020.

289

INSPECT application development

291   Specimens and results were tracked through the processing pipeline using the INSPECT

292   (Instant Service Platform for Emergency COVID-19 Tests) application. This Laboratory

293   Information Management System (LIMS) was designed specifically for tracking SARS-CoV-2

294   tests, and includes tracking of specimen ID, plate layouts, plate barcodes, RT-qPCR test

295   results, and participant IDs. All code and protocols needed to create a lab-tailored version of the

296   INSPECT app are freely available on GitHub (https://github.com/SEARCH-Alliance/inspect) and

297   protocols.io (20).

SEARCH sample processing, RNA extraction, and RT-qPCR

299   Sample processing and viral RNA extraction was performed using a KingFisher™ Flex

300   automated sample preparation machine (Thermo Fisher, Waltham, MA, USA) and an Eppendorf

301   epMotion® 5070 automated liquid handling workstation (Enfield, CT, USA). RNA was extracted

302   with the Omega Bio-tek Mag-Bind Viral DNA/RNA kit. A detailed protocol of the RNA extraction

303   process used in the SEARCH study is available on protocols.io (21). Following RNA extraction

304   of samples, SARS-CoV-2 detection was performed using a miniaturized and automated RT-

305   qPCR procedure. Viral RNA was detected using the TaqPath COVID-19 Combo Kit

306   (ThermoFisher Scientific, Waltham, MA, USA). This viral RNA detection kit is approved by the

307   Emergency Use Authorization (EUA) authority of the US FDA for the detection of SARS-CoV-2,

308   and targets three regions of the SARS-CoV-2 genome - N gene, S gene, and ORF1ab gene - as

309   well as an internal positive control, MS2. The miniaturization of the RT-qPCR process (from the

310   standard 25 µL to a 3 µL reaction volume) involved the use of two Mosquito robotic liquid

311   handlers (STP Labtech Ltd., formerly TTP Labtech Ltd., Boston, MA, USA): a 16-channel liquid

312   handler (HV Genomics), and an HV X1 hit/cherry picker single-channel liquid handler. RT-qPCR

313   was performed on a QuantStudio™ 5 Real-Time PCR System (Applied Biosystems). A detailed

314   protocol of the miniaturized and automated RT-qPCR process used in this study is available on

315   protocols.io (22). Using the TaqPath COVID-19 Multiplex Real-Time RT-PCR Assay, samples

316   are considered positive when at least two out of three viral target genes (S gene, N gene, and

317   ORF1ab) amplify using a threshold cycle (Ct) of 37 cycles, and samples are considered

318   negative when none of the three viral target genes amplify but the internal control (MS2) does

319   amplify. Inconclusive test results are those in which only one of three viral target genes

320   amplifies, while invalid tests are those in which no viral target genes amplify, and the internal

321   control also fails to amplify. Samples that produced inconclusive and invalid results from the

322   initial analysis were re-extracted and re-amplified, and the decision tree recommended by the

323   manufacturer (Thermo Fisher) was used to determine the final result; data presented here are

324   the final results obtained after re-extraction and re-amplification, in cases where this was

325   necessary.

Validation of RT-qPCR miniaturization and research workflow

327   A technical validation of the RT-qPCR miniaturization was performed by comparing the

328   miniaturization reactions to full-scale reactions. RT-qPCR performance of the miniaturized

329   reactions was compared to published results for full-scale reactions to evaluate equivalency (Fig

330   S1). The limit of detection (LOD) was calculated for the miniaturized reactions using two

331   different methods: (1) SARS-CoV-2 viral RNA was spiked into the RT-qPCR reaction in different

332   concentrations (1-128 viral genome equivalents per reaction) along with RNA extracted from

333   negative NP control samples; (2) SARS-CoV-2 viral RNA was spiked into negative NP control

334   samples in lysis buffer, before RNA extraction, in different concentrations (1-100,000 viral

335   genome equivalents/mL input sample) (Fig S2). RT-qPCR performance of the miniaturized

336   reactions were found to be equivalent to the full-scale reactions (Fig S1). The limit of detection

337   for the miniaturized reactions (using the evaluation criteria recommended by the manufacturer,

338   and requiring all three replicates to show a positive result) was found to be 500 viral RNA

339   copies/mL input sample, with >4 viral RNA copies per RT-qPCR reaction (Fig S2).

340   Samples that tested positive through the research pipeline were subjected to

341   confirmatory clinical tests by a collaborating Clinical Laboratory Improved Amendments (CLIA)

342   lab at UCSD. A number of negative samples were also sent to the collaborating CLIA lab to

343   confirm their negative status as determined through the research pipeline. In total, 21 positive

344   and 141 negative samples obtained through the research pipeline were re-tested by the

345   collaborating CLIA lab: all 141 negative samples were confirmed negative, and 18/21 positive

346   samples were confirmed as true positives, with 3/21 samples returning a false-positive result.

347   The true positives were reported to the study participants and the SD County Public Health

348   Department.

EXCITE Lab

350   After the SEARCH study (the initial proof-of-concept study) was complete, the

351   methodology developed by the SEARCH team was adapted to establish the Expedited COVID-

352   19 Identification Environment (EXCITE) lab, a CLIA-certified laboratory at UCSD dedicated to

353   COVID-19 testing. The EXCITE lab was developed to provide rapid, asymptomatic population

354   screening for UCSD students/faculty/staff, and also partnered with local public and private

355   preschool-grade 12 schools and SDFD to test their populations. The UCSD Institutional Review

356   Boards (IRB) provided human subject protection oversight of the data obtained by the EXCITE

357   lab (IRB approval #210817X).

Translation of the research workflow into the CLIA environment

359   The research workflow from the SEARCH study was adapted for clinical use by the

360   EXCITE lab, with the goal of repeated screening of large populations as a component of

361   programs developed to safely increase educational and business activities during the COVID-19

362   pandemic. Five major changes to the SEARCH pipeline were implemented by the EXCITE lab

363   to improve patient acceptability, enhance the safety of testing personnel, increase assay

364   throughput, ensure compliance with College of American Pathologists (CAP) and CLIA

365   regulations, and enable reporting of clinical results to patients' medical records and to the

366   required public health agencies.

367   First, we validated anterior nares (AN) sample collection via self-swabbing. NP swabs

368   are considered the gold standard sample type used to test for SARS-CoV-2. However, these

369   swabs are uncomfortable for the patient and require collection by a clinical provider at close

370   proximity, which decreases compliance and increases cost and risk, making it infeasible for

371   large-scale repeated screening programs. Anterior nares swabs can be self-collected with

372   minimal discomfort, while providing comparable test results.

373   Second, to enable safer handling of large numbers of samples, we changed from sample

374   collection in VTM, in which viral particles remain infectious, to PrimeStore® Molecular Transport

375   Medium (MTM), which immediately inactivates the SARS-CoV-2 virus. Following validation with

376   MTM, we additionally validated sample collection in Mawi DNA Technologies iSWAB

377   Microbiome buffer (Mawi) as well as 5% sodium dodecyl sulfate (SDS). AN swabs in MTM,

378   Mawi, and SDS are referred to here as "ANM", "ANW", and "AND", respectively. All three media

379   types inactivate the virus, allowing for self-collection and safer handling, but Mawi and SDS

380   have the additional benefit of being non-toxic substances, allowing for unsupervised self-

381   collection of samples.

382   Third, to increase assay throughput, we centralized our operations from three research

383   laboratories located ~10 min drive apart into two adjacent rooms in the same building, and

384   obtained and integrated two Hamilton® Microlab STAR liquid handling systems for automated

385   accessioning and transfer of samples from collection tubes to 96-well plates prior to RNA

386   extraction (see "EXCITE sample accessioning, RNA extraction, and RT-qPCR" section below).

14

387   Fourth, we obtained a CLIA extension from the existing Biochemical Genetics high-

388   complexity CLIA laboratory in the Department of Pediatrics at UCSD, and established Standard

389   Operating Procedures for each aspect of the workflow.

390   Finally, we built secure links between the INSPECT application and the UCSD instance

391   of the EPIC electronic health record, as well as the California Reportable Disease Information

392   Exchange (CalREDIE) Electronic Lab Reporting (ELR) system, using Redox as the integration

393   application programming interface (API).

394   These changes were implemented in parallel, allowing us to translate the research

395   workflow into a clinical assay in only forty days. The EXCITE lab was designed to accommodate

396   up to 6,000 samples per day with next-day results.

Validation of anterior nares samples

398   We clinically validated our clinical workflow using AN swabs collected in MTM ("ANM"),

399   Mawi ("ANW"), and 5% SDS ("AND"). First, we performed a technical validation by determining

400   the LOD of all three sample types using contrived samples with a range of SARS-CoV-2 viral

401   particle (VP) concentrations, from 250 VP/mL up to 32,000 VP/mL, with each test performed in

402   triplicate. We demonstrated that the sensitivity of our clinical workflow is excellent, with a

403   technical LOD of 500 VP/mL for MTM and 250 VP/mL for Mawi and SDS (Table S2). Next, a

404   second technical validation was performed using contrived samples containing 1,000 VP/mL; a

405   minimum of 20 replicate samples were run per sample type, and a minimum of 19/20 were

406   required to return a positive result via RT-qPCR (see "EXCITE sample accessioning, RNA

407   extraction, and RT-qPCR" section below). All ANM and AND replicates returned a positive

408   result, and 19/20 ANW replicates returned a positive result (Table S3). Last, we performed

409   clinical validation on all three sample types, first validating ANM samples and then using the

410   validated ANM as a comparator to clinically validate ANW and AND. We used remnant AN

411   samples collected in MTM from 30 positive cases and 32 negative cases, kindly provided by

412   Helix OpCo, LLC (San Diego, CA, USA). These samples had previously been tested/validated

413   by Helix under their EUA (https://www.fda.gov/media/140420/download), and the test results

414   obtained from Helix were used as the comparator for our results (Table S4). Following ANM

415   validation and EUA authorization, we validated ANW and AND sample types with clinically-

416   obtained positive and negative cases for SARS-CoV-2, and using the recently-validated ANM

417   sample type as the comparator. Clinical validation required a minimum of 90% compliance

418   between the EUA authorized comparator and the experimental sample types on the same

419   samples. For ANW, 34 positives and 54 negatives were tested, and for AND, 38 positives and

420   55 negatives were tested (Table S4). The sensitivity (the ability of the test to correctly identify

421   positives), specificity (the ability of the test to correctly identify negatives), and accuracy (overall

422   probability that a test is correct) for each sample type can be seen in Table 1.

423

424   **Table 1.** Sensitivity, specificity, and accuracy of anterior nares swabs in MTM (ANM), Mawi
425   (ANW), or 5% SDS (AND) media, tested for the presence of SARS-CoV-2 during clinical
426   validation. Numbers in brackets are 95% confidence intervals.

	Sensitivity	Specificity	Accuracy
ANM	100% (88.43 - 100)	100% (89.11 - 100)	100% (94.22 - 100)
ANW	100% (89.11 - 100)	100% (93.40 - 100)	100% (95.80 - 100)
AND	94.59% (81.81 - 99.34)	100% (93.40 - 100)	97.80% (92.29 - 99.73)

427

EXCITE sample collection

429   Self-swabbed anterior nares (AN) samples were collected using nylon flocked swabs

430   (https://renonlab.en.made-in-china.com/product/zKEnIjuyEdrC/China-Medical-Virus-Test-

431   Collection-Nylon-Flocked-Nasopharyngeal-Nasal-Swabs.html), which were placed in tubes

432   containing 1 mL of either MTM, Mawi, or 5% SDS. All participants >12 years of age self-

433   collected samples, and children 12 years of age or younger in participating schools had samples

434   collected by trained staff at each school. Sample collection occurred on-site at participating fire

435   departments and schools, and all samples were sent daily to the EXCITE lab for testing. For

436   UCSD participants, sample test kits were available in dedicated vending machines throughout

16

437   campus, with sample drop sites located next to the vending machines that were collected

438   multiple times per day for testing by the EXCITE lab. EXCITE samples reported in this study

439   were collected between September 15, 2020 and February 5, 2021.

440   **EXCITE sample accessioning, RNA extraction, and RT-qPCR**

441   The workflow of the EXCITE lab was modeled after the SEARCH study, but updated and

442   further automated to increase throughput. Sample accessioning was performed using

443   Hamilton® Microlab STAR liquid handling systems. RNA was extracted using the MagMax Viral

444   Pathogen (MVPII) kit, and extraction was semi-automated via the use of an epMotion® 5075

445   liquid handling workstation (Eppendorf) and a KingFisher™ Flex purification system (Thermo

446   Fisher). A detailed protocol of the semi-automated sample accessioning and RNA extraction

447   process used by the EXCITE lab is available on protocols.io (23).

448   Viral RNA was detected using the TaqPath COVID-19 Combo Kit (ThermoFisher

449   Scientific, Waltham, MA, USA). RT-qPCR reaction preparation was performed using a

450   Mosquito® HV Genomics robotic liquid handler (SPT LabTech), and miniaturized 3 μL RT-

451   qPCR reactions were performed on a QuantStudio™ 7 Pro Real-Time PCR System (Applied

452   Biosystems). A detailed protocol of the miniaturized and automated RT-qPCR process used by

453   the EXCITE lab is available on protocols.io (22). Test results were determined as described

454   above in the "SEARCH sample processing, RNA extraction, and RT-qPCR" section. Samples

455   that tested positive through the EXCITE pipeline were re-extracted and re-amplified to confirm

456   the positive result, and then reported to SD County. EXCITE participants received the results of

457   every test they submitted, regardless of positivity.

458   # Data analysis and visualization

459   Data curation was conducted in R (version 4.0.3) using the 'tidyverse' (version 1.3.0)

460   package (24) and the associated 'readr' (version 1.4.0) package. Statistical analyses including *t*-

461   tests and Kruskall-Wallis tests were performed in R (version 4.0.3) or Python (version 3.6.11).

17

462   Chi-square tests and data summaries from Tables 5 and 6 were performed/created using SAS

463   (version 9.4).

464   Data visualization was accomplished using a combination of R (version 4.0.3), Python

465   (version 3.6.11), Tableau (Desktop version 2019.2.5 and Server version 2019.2.0), Excel 2010

466   (version 2103), Inkscape (version 1.0), and Leaflet (version 0.7.7). Figs 1C; S1; S2; S3; and S6

467   were created in Excel and edited in Inkscape. Figs 1A; 1B; 2; and 4 were created in Tableau

468   and edited in Inkscape. Figs 3 and 5 were created in Python. Figs 6; 8; S4; S5; and S6 were

469   created in R using the following packages: 'lubridate' (version 1.7.9.2) (25); 'ggstatsplot' (version

470   0.7.0) (26); 'ggpubr' (version 0.4.0); 'tidyverse' (version 1.3.0) (24) and the associated packages

471   'readr' (version 1.4.0), 'readxl' (version 1.3.1), 'ggplot2' (version 3.3.3), and 'ggpubr' (version

472   0.4.0). Figs 6 and 8 were created in Leaflet (https://leafletjs.com/) and OpenStreetMap

473   (https://www.openstreetmap.org/copyright), using coordinate data from zipcodeR package

474   (https://cran.r-project.org/web/packages/zipcodeR/index.html) and Google Maps

475   (https://maps.google.com).

476   Full datasets, as well as scripts for data analysis and visualization used in this

477   publication, are made available at https://osf.io/3fguz/.

478

Results and Discussion

Overall Testing Results

481   Samples were collected for the SEARCH study between April 17 and June 30, 2020,

482   and by the EXCITE lab between September 15, 2020 and February 5, 2021. The SEARCH

483   study was designed to screen healthcare workers and first responders from San Diego County

484   (SD County); in particular, employees from Rady Children's Hospital San Diego (RCHSD), Rady

485   Children's Institute for Genomic Medicine (RCIGM), Scripps Health, and the San Diego Fire-

486   Rescue Department (SDFD) were screened, along with a small number of employees from

487   other institutions who heard of the study by word of mouth and were allowed to participate. The

488   EXCITE lab was designed for repeated screening of UCSD students and employees, but has

489   also partnered with a number of private and public preschool-grade 12 schools and SDFD to

490   provide repeated testing of their members. A recent study highlighted the potential positive

491   implications of institutions expanding their COVID-19 testing efforts to include members of

492   surrounding communities, which can benefit the institution itself as well as the community as a

493   whole (27).

494   Both SEARCH and EXCITE included repeat testing of participants; in total, 8,066

495   nasopharyngeal (NP) swabs were obtained from 6,376 individuals via the SEARCH study, and

496   153,516 anterior nares (AN) swabs were obtained from 28,293 individuals via the EXCITE lab.

497   During the time period of this study, the EXCITE lab processed an average of 1,124 samples

498   per day. Additionally, the average total time from sample barcode scan to return of results was

499   15.2 ± 0.03 h, with an average of 6.6 ± 0.01 h of in-lab processing time (Fig S3). Results were

500   returned within 24 h of receipt at the lab for 98.1% of samples, and between 24-60 h for 1.2% of

501   samples. The latter were largely samples that returned with Inconclusive or Invalid results on

502   the first analysis run, and were analyzed a second time before reporting a clinical result. We

503   note that there was a small proportion (0.7%) of samples with processing times >60 h; these

504   were primarily samples for which the lab did not initially receive the required patient-level

505   demographic information to report a clinical result, and therefore needed to request additional

506   information from the ordering healthcare provider prior to returning results.

507   The breakdown of test results by sample type is presented in Table 2. In the SEARCH

508   study, 21 samples initially returned a positive result based on the RT-qPCR performed by the

509   collaborating SEARCH research labs. Samples from all positive tests based on the research

510   testing pipeline were sent to a CLIA-certified lab for validation using their clinical testing pipeline

511   before results were returned to participants. Of the 21 initial positive tests, 18 were validated as

512   true positives, and three were returned as false positives. Therefore, the false-positive rate for

513   the SEARCH study was 0.037%. Because the EXCITE lab is itself a CLIA-certified lab, positive

514   results were reported directly without external validation. Of the 752 true positive results

515   identified through both SEARCH and EXCITE, 715 tests were obtained from unique individuals,

516   with 35 individuals testing positive on two different occasions and one individual testing positive

517   on three different occasions. The average time between positive tests for the same individual

518   was 5 days; no individuals from this study were identified to be re-infected after recovering from

519   COVID-19.

520   While the SEARCH study only collected NP swabs in VTM, the EXCITE lab used AN

521   swabs in three different preservation media; MTM, Mawi, and 5% SDS, corresponding to ANM,

522   ANW, and AND sample types, respectively. All three media inactivate the SARS-CoV-2 virus,

523   enabling self-collection. The ANM sample type was validated first, but was soon replaced by

524   ANW and AND, which are non-toxic, allowing for unobserved self-collection. AND samples

525   produced invalid results significantly more often than samples collected in other preservation

526   media (Table 2); AND samples comprised only 4.7% of all samples, but 67.8% of all invalid test

527   results. As a consequence, the EXCITE lab quickly discontinued the use of AND samples,

528   focusing instead on ANW samples.

529   **Table 2.** SARS-CoV-2 RT-qPCR test results obtained from SEARCH and EXCITE, by sample
530   type: AND (anterior nares swab in 5% SDS); ANM (anterior nares swab in MTM); ANW (anterior
531   nares swab in Mawi); NPV (nasopharyngeal swab in VTM). All NPV samples were obtained
532   from SEARCH, and all AND, ANM, and ANW samples were obtained from EXCITE. Samples
533   where no viral target genes amplified but the internal control did amplify were considered
534   negative. Samples where at least two out of three viral target genes amplified were considered
535   positive. Samples where neither the viral target genes nor the internal control amplified were
536   considered invalid. Samples where only one out of three viral target genes amplified were
537   considered inconclusive.

	AND	ANM	ANW	NPV	Total
	n (%)	n (%)	n (%)	n (%)	n (%)
Negative	7288 (96.56)	20959 (99.90)	124182 (99.35)	8032 (99.58)	160461 (99.31)
Positive	38 (0.50)	15 (0.07)	681 (0.54)	18 (0.22)	752 (0.47)
Invalid	221 (2.93)	3 (0.01)	90 (0.07)	12 (0.15)	326 (0.20)
Inconclusive	1 (0.01)	2 (0.01)	36 (0.03)	4 (0.05)	43 (0.03)

| *Total*	*7548 (100)*	*20979 (100)*	*124989 (100)*	*8066 (100)*	*161582 (100)*

538

539   The percentage of positive tests from the SEARCH study was very low: only 17

540   participants (0.27%) had a positive COVID-19 test throughout the 2.5 month duration of the

541   study (one of these participants submitted two positive samples, resulting in the count of 18

542   positive NPV test results in Table 2), and positive cases were spread relatively evenly

543   throughout the timeframe of the study, with the rolling average always below 1% positivity (Fig

544   1A). Comparatively, SD County testing reported much higher positivity, with rolling average

545   positivity ranging from ~2-7% over the same time period (Fig 1C). In the EXCITE lab, positivity

546   changed over time, starting low from mid-September through mid-November, and then rising

547   following the Thanksgiving holiday (Nov 26, 2020), and rising again to a peak in early January

548   2021, after the winter holidays (Fig 1B). The number of tests performed per day increased

549   throughout the fall, as the program was ramped up to test students residing in campus-owned

550   housing or coming to campus every two weeks, and then decreased in late December 2020

551   when many students left the UCSD campus for the holidays. Overall testing was highest in early

552   January 2021, when students residing in campus-owned housing or coming to campus were

553   required to participate in intensive testing upon their return to campus (at days 1, 5, and 10 after

554   return), and then went to a weekly testing cadence thereafter (see "Return to Learn at UCSD"

555   section below for more details). The EXCITE data show a similar trend in positive test rates to

556   the data from data from SD County (Fig 1C), except that the increase in positive cases in the fall

557   started later (at the end of November 2020 for EXCITE, compared to the beginning of

558   November for SD County) and show a slightly earlier drop in positive cases in January 2021 at

559   EXCITE. The positivity rate of the SD County data was much higher than the rates reported by

560   both SEARCH and EXCITE over the same time frame; the rolling average positivity rate for

561   SEARCH never rose above 1%, and for EXCITE was less than 2% at its peak, as compared to

562   the SD County data, where test positivity ranged from 2-15% across the same time period (April

563   17, 2020 - February 5, 2021). We note that the populations being tested by SD County are

564   different from those tested in our study. Our data collection involved repeated screening of

565   asymptomatic populations, while samples collected by SD County are more often from

566   individuals who exhibit symptoms or have been exposed to a known COVID-19 case, likely

567   explaining the large discrepancy in positivity rates. In particular, students at UCSD who were

568   experiencing symptoms were referred to the Center for Advanced Laboratory Medicine (CALM),

569   a separate CLIA-certified laboratory on campus, to be tested. Similarly, students and staff at the

570   preschool-grade 12 partner schools were asked to stay home and obtain testing at SD County

571   testing sites if they experienced any symptoms.

572   The winter holidays are typically a very social time for people living in the US, and

573   despite the COVID-19 pandemic, millions of Americans traveled during the holidays in late

574   2020, contributing to a sharp increase in cases reflected both in our data and in the SD County

575   data. The decline in UCSD cases throughout January 2021 was due to early detection of cases

576   after return from winter break, minimal transmission on campus, and reduced community

577   transmission in SD County. The decline in SD County cases observed in January 2021 is likely

578   due to people returning to their homes following the winter holiday and the subsequent

579   decrease in travel and social gatherings, and to a lesser extent, an increase in vaccination

580   rates, which began in late 2020. Countries with higher vaccination rates in early 2021, including

581   the UK and Israel, saw sharp declines in new COVID-19 cases and hospital admissions in

582   February 2021, highlighting the remarkable efficacy of these vaccines, even after one dose

583   (28,29).

584

22

A

585

B

586
587

Fig 1. COVID-19 test results and rolling average of positivity rate for (A) SEARCH study participants (Apr 17 - Jun 30, 2020), (B) EXCITE lab participants (Sep 15, 2020 - Feb 5, 2021), and (C) San Diego County testing results (Apr 17, 2020 - Feb 5, 2021).

Almost all of the positive tests for this study came from the EXCITE lab dataset, and

most positive tests were obtained between mid-November, 2020, and mid-January, 2021.

UCSD participants made up most of the positive tests, which was expected because most of the

EXCITE testing was conducted on UCSD students and staff (Fig 2). Only SDFD and UCSD

participants were tested by both SEARCH and EXCITE (Fig 2). However, the UCSD population

tested during the SEARCH study was different than that tested by the EXCITE lab. During the

SEARCH study, some UCSD employees involved in the study chose to participate in testing.

While these employees likely also participated in testing through the EXCITE lab, they were not

the main targets of either testing effort; the SEARCH study was designed to screen healthcare

workers and first responders, and the EXCITE lab was established to screen students, faculty,

and staff at UCSD and some partner institutions, with a focus on testing schools.

Fig 2. Log-transformed graph of COVID-19 testing results over time (by day), separated by source group. Participants being tested belonged to one of seven groups: RCHSD (Rady Children's Hospital San Diego); Scripps Health (Scripps HealthCare); SDFD (San Diego Fire-Rescue Department); UCSD (University of California, San Diego); Private Schools (preschool-grade 12); Public Schools (preschool-grade 12); Other/Unspecified (healthcare workers from other locations).

COVID-19 case data from SD County show that the 20-39 age group represents the highest number of cases (and case rates), followed by the 40-59 age group (Fig 3). The age groups represented by children (0-9 and 10-19) reported the lowest number of cases in the County. Within the EXCITE data from this study, participants in the 20-39 age group also made up the majority of cases, with all other age groups falling well below (Fig 3). This is largely due to the demographics of the EXCITE testing population, where the majority of participants were university students. We note that the 10-19 age range represents a higher proportion of cases in the EXCITE data than in the County data, also likely because of the large number of university students in the 18-19 age range in our study.

25

Fig 3. Number of positive cases per week, separated by age group. Top: San Diego County COVID-19 cases over time (Sep 15, 2020 to Feb 5, 2021). Bottom: EXCITE lab COVID-19 cases over the same timeframe.

No significant differences in viral load (estimated by Ct value) were observed for participants from different age groups (Fig S4). Previous studies have varied in their reports of viral loads in patients of different age groups. Some, like this current study, have not found any significant correlation between viral load and age groups (30–33), while others have (34–37). In the studies that did observe a difference, the results are conflicting: Euser et al. (37) reported that children <12 years had lower viral loads than adults, while Heald-Sargent et al. (36) reported children <5 years had higher viral loads than older children and adults. Additionally, Hasanoglu et al. (35) reported decreasing viral load with increasing age in adults, while To et al. (34) reported the opposite trend. Consistent with previous reports (10,31), we did not find any significant difference in viral load between male and female participants ($t = 0.02$, df = 645.7, $p = 0.98$).

Only two of the three SARS-CoV-2 target genes were required to amplify for a test to be considered positive. The S-gene was the most common 'dropout' (i.e. the gene that failed to

26

641 amplify), occurring in approximately 10% of positive cases; N-gene and ORF1ab dropouts

642 occurred in approximately 1-2% of positive cases, respectively. With the exception of the cases

643 in this study infected with the B.1.1.7 SARS-CoV-2 variant of concern, which show a

644 characteristic S-gene dropout with low Ct values (<30) for the other two viral genes (38),

645 samples with viral gene dropouts had higher average Ct values (i.e. lower viral load) as

646 compared to samples without dropouts (Fig S5); samples containing gene dropouts had an

647 average Ct value of 32.3 ± 1.1, while samples without dropouts averaged 23.0 ± 5.3 (t = -29.7,

648 df = 2.2, p = 0.001). Seven cases were identified that were consistent with the B.1.1.7 variant

649 (9.2% of all cases with S-gene dropouts), and the average Ct value for these seven cases was

650 21.9 ± 5.5.

Symptom Reporting

652   Symptom reporting differed between SEARCH and EXCITE (Fig 4). In total, SEARCH

653 participants filled out 7,489 symptom questionnaires (Table 3), and EXCITE participants filled

654 out 18,318 (Table 4). Therefore, 92.8% of SEARCH samples were accompanied by symptom

655 reporting, compared with just 11.9% of EXCITE samples. This discrepancy is due to the

656 different nature of each screening system. The SEARCH study was designed as a prospective

657 research study, so occupation and symptom information was requested from all participants.

658 The EXCITE lab was designed for high-throughput screening of asymptomatic populations, with

659 no UCSD participants being asked to report symptoms at the time of testing, and participants

660 from other partners being asked an abbreviated set of questions. Additionally, EXCITE

661 participants were generally assumed to be asymptomatic, because any symptomatic individuals

662 were encouraged to stay home and seek other means of testing. Conversely, at the time when

663 SEARCH was implemented (April 2020), it was the only means of obtaining a COVID-19 test for

664 many participants, resulting in a number of participants seeking out testing through SEARCH

665 specifically because they were exhibiting symptoms they felt might be related to COVID-19. The

666   timing of the SEARCH study also overlapped with the end of flu season, potentially explaining

667   the higher number of participants reporting symptoms at the beginning of the study as

668   compared to later in the study (Fig 4A). Indeed, when SEARCH participants waiting in line to be

669   tested were asked why they chose to participate, their reasons mostly fell within four common

670   themes: (1) early in the study, many believed their symptoms could represent COVID-19 illness

671   but were unable to qualify for clinical testing because they were "not sick enough" per the

672   testing triage protocols in place at the time; (2) later in the study, others believed their symptoms

673   more likely represented seasonal allergies than COVID-19 but wanted to confirm, and

674   understood the importance of reporting these symptoms nonetheless; (3) some reported intense

675   stress regarding the pandemic and believed their symptoms of headache, fatigue, or muscle

676   aches might be due to worry or poor sleep, but again wanted to confirm; (4) finally, several said

677   they sought the privacy of testing outside their own healthcare workplaces. These unanticipated

678   explanations for study participation illuminate some unmet needs for frontline workers in

679   healthcare environments during the uncertainties of an unprecedented pandemic.

Fig 4. Symptom reporting by (A) SEARCH participants and (B) EXCITE participants over time.

Table 3. Symptom reporting by SEARCH participants who completed a symptom questionnaire at the time of testing. Results are per test, not per participant, in the case of participants testing on multiple occasions. Invalid and Inconclusive tests are included in the "All Tests" column but are not represented in subsequent columns.

Symptoms	All Tests	Negative Tests	Positive Tests
	n (%)	n (%)	n (%)
No symptoms	6746 (90.08)	6723 (90.17)	10 (55.56)
Any symptoms	743 (9.92)	733 (9.83)	8 (44.44)
Fever	18 (0.24)	15 (0.20)	3 (16.67)
Chills	47 (0.63)	43 (0.58)	4 (22.22)
Cough	152 (2.03)	147 (1.97)	4 (22.22)
Sore throat	177 (2.36)	173 (2.32)	4 (22.22)

29

Trouble breathing	45 (0.60)	44 (0.59)	1 (5.56)
Stuffy nose	205 (2.74)	200 (2.68)	5 (27.78)
Runny nose	190 (2.54)	185 (2.48)	5 (27.78)
Nausea	77 (1.03)	74 (0.99)	3 (16.67)
Vomiting	13 (0.17)	13 (0.17)	0 (0)
Diarrhea	61 (0.81)	58 (0.78)	3 (16.67)
Fatigue	169 (2.26)	165 (2.21)	4 (22.22)
Myalgia	149 (1.99)	143 (1.92)	5 (27.78)
Rash	24 (0.32)	24 (0.32)	0 (0)
Total	*7489 (100)*	*7456 (100)*	*18 (100)*

688

689　**Table 4.** Symptom reporting by EXCITE participants who completed a symptom questionnaire
690　at the time of testing. Results are per test, not per participant, in the case of participants testing
691　on multiple occasions.

Symptoms	All Tests	Negative Tests	Positive Tests
	n (%)	n (%)	n (%)
No symptoms	18249 (99.62)	18093 (99.68)	90 (89.11)
Any symptoms	69 (0.38)	58 (0.32)	11 (10.89)
Fever	7 (0.04)	2 (0.01)	5 (4.95)
Cough	11 (0.06)	8 (0.04)	3 (2.97)
Trouble breathing	2 (0.01)	2 (0.01)	0 (0)
Fatigue	10 (0.05)	6 (0.03)	4 (3.96)
Headache	25 (0.14)	20 (0.11)	5 (4.95)
Anosmia	4 (0.02)	2 (0.01)	2 (1.98)
Sore throat	9 (0.05)	8 (0.04)	1 (0.99)
Stuffy/runny nose	28 (0.15)	23 (0.13)	5 (4.95)
Nausea	8 (0.04)	8 (0.04)	0 (0)
Diarrhea	6 (0.03)	6 (0.03)	0 (0)
Total	*18318 (100)*	*18151 (100)*	*101 (100)*

692

693　　　　　Among all SEARCH participants, the most common symptoms reported at the time of

694　testing were stuffy nose, runny nose, sore throat, fatigue, and cough (Table 3). The least

695　common symptoms reported were vomiting, trouble breathing, and fever. Among the

696　participants who tested positive and also completed a symptom questionnaire, the most

697　common symptoms at the time of testing were stuffy nose, runny nose, and myalgia (muscle

698　pain), and the least common symptoms were rash, vomiting, and trouble breathing (Table 3).

699　More than 90% of participants who tested negative reported no symptoms, compared with

700　~55% of participants who tested positive; nearly 45% of participants who tested positive

30

701   reported at least one symptom at the time of their test, with five being the average number of

702   symptoms reported per person, out of a possible 14. The average age of SEARCH participants

703   who completed symptom questionnaires was 42.9 ± 12.2. Of the 18 positive tests, 17 belonged

704   to different individuals. One participant tested positive twice, reporting symptoms at the time of

705   their first positive test, and reporting no symptoms at the time of their second positive test, nine

706   days later. This participant tested negative on their third test, 16 days after their first positive

707   test.

708   Among the EXCITE participants who completed symptom questionnaires, the most

709   common symptoms reported at the time of testing were headache and stuffy/runny nose (Table

710   4). The least common symptoms reported were trouble breathing and anosmia (loss of sense of

711   smell). Among the participants who tested positive and also completed a symptom

712   questionnaire, the most common symptoms at the time of testing were fever, headache, and

713   stuffy/runny nose, and the least common symptoms were trouble breathing, nausea, and

714   diarrhea (Table 4). More than 99% of participants who tested negative reported no symptoms,

715   compared with 89% of participants who tested positive; nearly 11% of participants who tested

716   positive reported at least one symptom at the time of their test, with two being the average

717   number of symptoms reported per person, out of a possible 10. The average age of EXCITE

718   participants who completed symptom questionnaires was 24.1 ± 16.4.

719   Different symptom questions were asked of SEARCH and EXCITE participants. Some

720   symptoms characteristic of COVID-19, such as anosmia (loss of sense of smell), were not

721   included in the SEARCH study because sample collection began before this symptom was

722   recognized as an indicator of COVID-19. Other symptoms, such as myalgia (muscle soreness)

723   and rash, were included in the SEARCH questionnaire but not the EXCITE questionnaire. This

724   is because only the most common cold, flu, and COVID-19 symptoms were included in the

725   EXCITE questionnaire.

726   Of the 17 SEARCH patients who tested positive for SARS-CoV-2, 11 were available for

727   regular telephone follow-ups, undertaken for 2-3 weeks in order to gain an understanding of

728   symptom progression. Only three of these 11 people reported symptoms at the time of testing:

729   one reported fever, one reported fatigue, muscle aches, and chills, and one reported cough,

730   nasal congestion, and sore throat. Among the eight who did not report symptoms at the time of

731   testing, five developed symptoms within 24 h of participating in the study, ranging from ageusia

732   (loss of sense of taste) ($n = 2$) to sore throat with rhinorrhea (runny nose) ($n = 1$) to fever and

733   cough ($n = 2$). One patient developed anosmia within 72 h, followed by severe fatigue and later

734   a cough. Finally, two patients reported no symptoms of illness by two and three weeks,

735   respectively. None of the ill participants required hospitalization, though one had an extended

736   productive cough that began two days after testing positive and was placed on work leave for

737   three weeks. While more than half of the SEARCH participants who tested positive for SARS-

738   CoV-2 in our study did not report any symptoms at the time of testing, most went on to develop

739   symptoms within 2-3 days of their first positive test, suggesting that within our study, being pre-

740   symptomatic at the time of testing was more common than having an asymptomatic infection.

741   Interestingly, shortness of breath/trouble breathing, which is considered a hallmark symptom of

742   COVID-19, was reported by only one positive participant at the time of testing across both

743   SEARCH and EXCITE, suggesting that this symptom may typically develop later on in the

744   progression of the disease, as noted by some previous studies (39,40), and may not be a good

745   screening question to determine whether a person qualifies for a COVID-19 test. Reporting of

746   the prevalence of shortness of breath/trouble breathing as a major symptom is inconsistent: one

747   study also found shortness of breath to be a less common symptom (41), but other studies have

748   reported shortness of breath to be one of the most common symptoms (42–44). However, it

749   should be noted that these studies involved assessing symptoms in hospitalized patients, or

750   even patients who suffered fatal cases of COVID-19, which represents a small fraction of

751   infections.

752   Viral load was significantly correlated with the presence of symptoms for all three target

753   genes (Fig 5), and only one of the 19 positive tests that were accompanied by a positive

754   reporting of symptoms contained a gene dropout, suggesting that presentation of symptoms

755   may indicate higher viral load in the body. Some previous studies have identified a correlation

756   between viral load and symptom severity (45,46), but most of these studies were conducted on

757   hospitalized patients. Conversely, other studies have found viral loads to be unchanged (13) or

758   even higher (35) in asymptomatic patients as compared to symptomatic patients. Interestingly,

759   overall Ct values from SEARCH positives were higher than those from EXCITE positives,

760   regardless of symptom reporting (t = -2.7, df = 18.1, p = 0.01) (Fig 5). It is possible that

761   differences in the tested populations, sample type (nasopharyngeal versus anterior nares

762   swabs), collection media, or RNA extraction kits used in SEARCH compared to EXCITE

763   contributed to this observation.

764
765

766
767   **Fig 5.** Ct values of three SARS-CoV-2 gene targets as a function of symptom reporting (n =
768   119). Samples from positive participants who also reported having symptoms had significantly
769   lower Ct values (i.e. higher viral load) for all three gene targets, as compared with samples from
770   positive participants who reported no symptoms (independent t-test p-value for N-gene,
771   ORF1ab, and S-gene = 0.023, 0.031, 0.044, respectively).

772

773

Healthcare Workers and First Responders

774

775   In order to keep the healthcare worker and first responder data together, we have

776   included the SDFD first responders who were tested through the EXCITE lab in this section.

777   Therefore, this section contains data from 6,786 individuals, while the SEARCH study itself only

778   included 6,376 individuals. Of 11,964 total swabs, 3,935 were collected at RCHSD, 4,138 were

779   collected at Scripps Health locations, and 3,891 were collected by the EXCITE lab. A proportion

780   of study participants (1,167) chose to be tested on multiple occasions, some as many as 22

781   times, although the majority of high-repeat participants were those from SDFD who were tested

782   routinely through the EXCITE lab (Fig S6a). Of the 12,143 eligible Scripps employees who

783   received an invitation to participate in this study, 3,838 (31.6%) participated at least once. Of the

784   1,470 eligible SDFD employees, 1,162 (79.0%) participated in testing at least once: 120 (8.2%)

785   participated only in SEARCH, 410 (27.9%) participated only in EXCITE, and 632 (43.0%)

786   participated in both. Approximately 8,000 Rady employees received an email inviting them to

787   participate, but only approximately 6,000 opened the email. Additionally, this email was sent to

788   employees of Rady Children's Hospital San Diego (RCHSD), Rady Children's Institute for

789   Genomic Medicine (RCIGM), and Rady Children's Specialists of San Diego (RCSSD), but on

790   the intake form, only RCHSD was one of the pre-specified options, meaning employees of

791   RCIGM and RCSSD likely would have selected the "Other" option as their employer, or simply

792   not specified. A conservative estimate of participation, therefore, suggests that out of

793   approximately 8,000 eligible Rady employees, 1,220 RCHSD employees (15.3%) participated.

794   A more liberal estimate of participation would include both RCHSD and "Other" employees, and

795   only those employees who opened their invitation email, resulting in 1,562 employees being

796   tested out of an estimated possible 6,000 (26.0%). However, a small number of employees from

797   Sharp HealthCare were informed of this study by word-of-mouth and were allowed to

798   participate; these employees would likely have chosen "Other" or "Unspecified" as their

799   organization as well. The true proportion of the target population tested is therefore likely

800   somewhere between 15.3-26.0% for Rady employees. For simplicity, tables and Figs in this

801   section combine the employees who selected "RCHSD" and "Other/Unspecified" into a single

802   category, "Rady". A small number of UCSD Health employees (112) also opted to be tested one

803   or more times. These participants selected "UCSD" as their employer, but because UCSD

804   employees were not targeted by the SEARCH study, we cannot estimate the proportion of

805   employees tested for this population.

806   Participants were asked to add a job description on their intake forms. Because these

807   job descriptions were free-text and not pre-specified categories, a wide range of occupations

808   were reported. These occupations were manually combined into 14 major categories with the

809   remainder being assigned to "Other/Unspecified" (Table 5). Approximately one-third (34.0%) of

810   healthcare worker participants from Scripps and Rady were employed as nurses, with the next

811   most common job category being general healthcare worker (24.2%), followed by doctor

812   (11.9%). The proportions of nurses and doctors in this study is similar to their actual proportions

813   at the hospitals and clinics from this study. The most common occupation among COVID-19

814   positive participants was first responder (66.7%) - this is because SDFD members additionally

815   participated in repeated screening through the EXCITE lab in late 2020 and early 2021, and the

816   entirety of the positive first responder cases came from that later time period, when cases in SD

817   County were markedly higher. During the SEARCH study timeframe (April - June 2020), no

818   SDFD members tested positive through our pipeline, and the most common occupations testing

819   positive at that time were general healthcare workers and nurses (5 participants each). While

820   some of these participants were presumed to have contracted the virus from work, others were

821   able to trace their infection to other sources, such as a family gathering or a spouse with a

822   public-facing job.

823

824 **Table 5.** Occupations of healthcare workers and first responders.

Occupation	All Participants	Positive Participants
	n (%)	n (%)
Administrative	302 (4.45)	1 (1.96)
Dental worker	23 (0.34)	
Dentist	30 (0.44)	
Dietitian	34 (0.50)	
Doctor	689 (10.15)	1 (1.96)
First Responder	1242 (18.30)	34 (66.67)
Food Service	37 (0.55)	1 (1.96)
Healthcare worker (general)	1340 (19.75)	5 (9.80)
IT	43 (0.63)	
Management	332 (4.89)	2 (3.92)
Nurse	1884 (27.76)	5 (9.80)
Pharmacist	76 (1.12)	
Pharmacy worker	29 (0.43)	
Student	35 (0.52)	1 (1.96)
Other/Unspecified	690 (10.17)	1 (1.96)
Total	*6786 (100)*	*51 (100)*

825   Demographic questions were asked of the participants; these questions were not

826 mandatory for participation, but the majority of participants responded to most or all of the

827 questions. The median age of healthcare workers was 41 for all target populations (Scripps

828 Health, Rady, and SDFD) (Fig 6, Table 6). The median age of those participants who tested

829 positive was significantly lower overall (35 years) and for healthcare workers (32 and 28 years

830 for Scripps Health and Rady participants, respectively), but not significantly lower for SDFD

831 participants (38.5 years) (Table 6). The overall data are consistent with CDC observations that

832 the median age of COVID-19 infections has declined over time, from >40 years to <36 years

833 between the months of March and July 2020 (47), and are in line with the median age (36

834 years) of confirmed COVID-19 cases among SD County residents at large

835 (https://www.sandiegocounty.gov/content/dam/sdc/hhsa/programs/phs/Epidemiology/COVID-

836 19%20Watch.pdf). Greene et al. (47) suggest that this decrease in the median age of confirmed

837 COVID-19 cases is a result of changing testing patterns, not changes in the epidemiology of

838 SARS-CoV-2 infection.

839   Female participants made up 74.0% of healthcare workers, which is representative of

840   the makeup of the workforce at the hospitals and clinics involved in this study, which are

841   approximately 74% female across Scripps Health and approximately 83% female at RCHSD.

842   Conversely, male participants made up 84.9% of first responders from SDFD, which is slightly

843   lower than the national proportion of male firefighters (96%) (https://nfpa.org). Of the

844   participants who tested positive for SARS-CoV-2, 70.6% of healthcare employees were female,

845   while 85.7% of SDFD employees were male. Overall, males were significantly more likely to test

846   positive than females (Table 6); however, when separated by source (Scripps Health, Rady,

847   SDFD), no differences were observed. This is because the majority of the positive tests came

848   from SDFD workers, who were predominantly male. Previous studies have suggested that

849   males may be more susceptible to this virus (48), but our results are proportional to the

850   populations tested in this study.

851   The majority of participants (72.1%) did not report their ethnicity, and almost one third

852   (28.4%) did not report their race (Table 6). For the SEARCH study, race and ethnicity were

853   presented as a single "check all that apply" question, which resulted in many people choosing

854   only a race, only an ethnicity, or neither. Most participants did not select an ethnicity, and those

855   that did select an ethnicity overwhelmingly selected Hispanic and did not also select a race. For

856   the SDFD participants who were tested through the EXCITE lab, race and ethnicity were

857   included as separate questions, which we believe improved reporting compliance. The EXCITE

858   demographic data are presented for every SDFD participant who was tested through EXCITE,

859   regardless of whether they were also originally tested through SEARCH. As a result, fewer

860   SDFD participants did not specify their ethnicity or race, as compared to healthcare workers

861   from Scripps Health and Rady (Table 6). SD County is ethnically diverse, with 34.1% of the

862   population identifying as Hispanic (https://www.census.gov/). However, only 15.3% of the

863   participants in this study selected Hispanic as their ethnicity. It is possible that the population in

864   our study is not representative of the population of SD County, but it is also possible that

37

865   Hispanic participants were less likely to report their ethnicity. There are many reasons why

866   people choose not to divulge this information in their medical or employment records, or when

867   participating in studies, including confusion over what category they fall into (especially when

868   there are limited and pre-specified categories from which to choose) as well as fear of

869   marginalization or receiving unequal quality of care (49). Additionally, both race and ethnicity

870   having been combined into a single "check all that apply" question for the SEARCH study likely

871   caused additional confusion. Most people who selected both a race and an ethnicity identified

872   as White and Hispanic. In the case of the SEARCH study, it may not have been clear to

873   participants that they were meant to select more than one option, and therefore most

874   participants selected the one answer they identified most strongly with.

875   More healthcare workers identified as Asian (16.9% for Scripps Health and 11.9% for

876   Rady, as compared to 2.7% for SDFD), while more SDFD participants identified as Other/Mixed

877   Race (9.0% for SDFD, compared to 2.0% for Scripps Health and 1.6% for Rady). In all three

878   populations, the majority of participants identified as White (44.8%, 47.7%, and 72.9% for

879   Scripps Health, Rady, and SDFD, respectively). However, direct comparisons between

880   healthcare workers and SDFD first responders may be inappropriate, since the methods used to

881   obtain demographic information were different for these populations. Overall, participants

882   identifying as White, Black/African American, and Other/Mixed Race were more likely to test

883   positive ($p = 0.03$), but no differences were observed when separated by source (Table 6). Non-

884   Hispanic SDFD participants were more likely to test positive than Hispanic or Unspecified

885   participants ($p = 0.02$), but no similar differences were observed among healthcare workers.

886

Fig 6. Age and sex distribution of (A) all participants and (B) positive participants from Scripps
Health and Rady healthcare systems, and from the San Diego Fire-Rescue Department
(SDFD). SEARCH participants who selected UCSD as their employer were excluded from this
Fig because they were not a targeted population for the SEARCH study. The dotted line in each
plot represents the median age.

893 **Table 6.** Demographic information of SEARCH healthcare worker participants (Scripps Health, Rady) and the San Diego Fire-
894 Rescue Department (SDFD) first responders. Participants who selected UCSD as their employer are included in the Overall
895 category. The Positive column includes individuals who tested positive for COVID-19 at least once, while the Negative column
896 includes individuals who never tested positive. Chi-square and *t*-tests were performed to test for differences among groups.
897 Differences were considered significant at $p \leq 0.05$ and are indicated in bold. The first column (Total) was not included in statistical
898 analysis and was included to show the demographics of the entire population, regardless of test result.

|	Total	Overall			Scripps			Rady			SDFR		
		Positive	Negative	*p*-value	Positive	Negative	*p*-value	Positive	Negative	*p*-value	Positive	Negative	*p*-value
Age, mean (SD), median	42.7 (12.1) 41	38.0 (11.4) 35	42.7 (12.1) 41	**0.005**	32.2 (8.4) 32	43.3 (12.4) 41	**0.005**	32.9 (11.2) 28	43.1 (12.5) 41	**0.03**	40.7 (11.5) 38.5	41.2 (10.2) 41	0.79
Age, n (%)													
< 30	947 (14.6)	13 (1.4)	934 (98.6)		4 (0.8)	494 (99.2)		**4 (1.7)**	229 (98.3)		5 (2.9)	165 (97.1)	
30-39	2027 (31.3)	20 (1.0)	2007 (99.0)		4 (0.3)	1156 (99.7)		2 (0.4)	471 (99.6)		14 (3.9)	345 (96.1)	
40-49	1562 (24.2)	9 (0.6)	1553 (99.4)	0.07	1 (0.1)	815 (99.9)	0.15	0 (0.0)	381 (100.0)	**0.04**	8 (2.3)	345 (97.7)	0.14
50-59	1224 (18.9)	6 (0.5)	1218 (99.5)		1 (0.1)	702 (99.9)		1 (0.4)	271 (99.6)		4 (1.7)	235 (98.3)	
60+	707 (10.9)	3 (0.4)	704 (99.6)		0 (0.0)	466 (100.0)		0 (0.0)	204 (100.0)		3 (8.6)	32 (91.4)	
Race, n (%)													
Unspecified	1926 (28.4)	10 (0.5)	1916 (99.5)		6 (0.5)	1183 (99.5)		4 (0.7)	586 (99.3)		0 (0.0)	114 (100.0)	
White	3432 (50.6)	**30 (0.9)**	3402 (99.1)		1 (0.1)	1719 (99.9)		3 (0.4)	795 (99.6)		26 (3.1)	821 (96.9)	
Black/AA	173 (2.6)	**4 (2.3)**	169 (97.7)		0 (0.0)	102 (100.0)		0 (0.0)	32 (100.0)		4 (10.3)	35 (89.7)	
Other/mixed	210 (3.1)	**4 (1.9)**	206 (98.1)	**0.03**	0 (0.0)	77 (100.0)	0.19	0 (0.0)	27 (100.0)	0.70	4 (3.9)	100 (96.1)	0.06
Asian	892 (13.1)	3 (0.3)	889 (99.7)		3 (0.5)	647 (99.5)		0 (0.0)	199 (100.0)		0 (0.0)	31 (100.0)	
Indigenous/NA	20 (0.3)	0 (0.0)	20 (100.0)		0 (0.0)	13 (100.0)		0 (0.0)	4 (100.0)		0 (0.0)	3 (100.0)	
Pacific Islander	133 (2.0)	0 (0.0)	133 (100.0)		0 (0.0)	88 (100.0)		0 (0.0)	21 (100.0)		0 (0.0)	24 (100.0)	
Ethnicity, n (%)													
Unspecified	4891 (72.1)	11 (0.2)	4880 (99.8)	**< 0.0001**	6 (0.2)	3254 (99.8)	0.10	5 (0.4)	1361 (99.6)	0.39	0 (0.0)	169 (100.0)	**0.02**
Hispanic	1036 (15.3)	**11 (1.1)**	1025 (98.9)		4 (0.7)	554 (99.3)		2 (0.7)	294 (99.3)		5 (3.0)	161 (97.0)	
Non-Hispanic	859 (12.7)	**29 (3.4)**	830 (96.6)		0 (0.0)	21 (100.0)		0 (0.0)	9 (100.0)		**29 (3.5)**	798 (96.5)	
Sex, n (%)													
Female	4270 (62.9)	16 (0.4)	4254 (99.6)	**< 0.0001**	8 (0.3)	2822 (99.7)	1.00	4 (0.3)	1244 (99.7)	0.47	4 (3.0)	129 (97.0)	0.78
Male	2373 (35.0)	**35 (1.5)**	2338 (98.5)		2 (0.2)	950 (99.8)		3 (0.8)	380 (99.2)		30 (3.0)	957 (97.0)	
Other/unspecified	143 (2.1)	0 (0.0)	143 (100.0)		0 (0.0)	57 (100.0)		0 (0.0)	40 (100.0)		0 (0.0)	42 (100.0)	

899

900   Participant-provided zip codes of residence were overlaid on a map of SD County (Fig

901   7). Study participants were spread throughout the County, with the highest concentration in San

902   Diego and the communities slightly further north towards La Jolla, which was expected given

903   that many of the healthcare systems monitored in this study are located in or near these

904   regions. However, the broad distribution of participants across SD County suggests that the

905   mobile testing sites were successful in enabling a more representative population to participate.

906   The distribution of positive participants largely matched the overall distribution of participants,

907   with concentrations in more heavily tested/populated areas. We note that even when

908   participants chose to be tested multiple times, they are represented only once in Fig 7.

909   (A)

910
911   (B)

Fig 7. Zip codes of residence of (A) all healthcare worker and first responder participants tested through the SEARCH study and EXCITE lab, and (B) all healthcare worker and first responder participants who tested positive for COVID-19. The deepness of color is proportionate to the number of participants who chose that zip code as their area of residence. The icon on both images represents the location of Rady Children's Hospital San Diego, where the permanent testing location was established during the SEARCH study.

UCSD and Preschool-Grade 12 Schools

Population Demographics

Data from UCSD, 11 private preschool-grade 12 (P-12) schools, and a group of 13 public P-12 schools located in SD County are included in this section. All participants were tested via the EXCITE lab at UCSD, and this section contains data from 27,252 individuals, with 21,221 coming from UCSD, 1,281 coming from public P-12 schools, and 4,750 coming from private P-12 schools. Because EXCITE was designed for repeated testing of asymptomatic populations, the majority of participants (81.7%) were tested on multiple occasions, some over 40 times (Fig S6b). The participants who tested most frequently were likely a combination of

929   EXCITE lab employees and UCSD student athletes, who were required to test frequently to

930   decrease the chance that their activities would be interrupted due to COVID-19 infections.

931   Demographic information was obtained from the participants. In this section, each

932   participant was counted once, regardless of how many times they participated in testing; for

933   positivity status, "positive" participants are those who tested positive through EXCITE at least

934   once, while "negative" participants are those who never tested positive. For UCSD participants,

935   demographic information was gathered from pre-existing student/employee records. For P-12

936   school participants, demographic information was gathered either as part of the consent

937   process for participation in this testing program, from student/employee records, or a

938   combination of the two. The median age was 22 for UCSD participants, 11 for public school

939   participants, and 16 for private school participants (Fig 8, Table 7). Most participants from each

940   group belonged to the 'student' age ranges appropriate for each educational facility. Overall,

941   participants were evenly split between male and female; however, within the P-12 schools, sex

942   was evenly split for student age ranges but skewed female for adult (teachers and staff) age

943   ranges (Fig 8). We found no differences in positivity rate by sex, overall or within any of the

944   three populations studied. Our finding was similar to the overall case reporting by sex by SD

945   County (https://www.sandiegocounty.gov/). However, SD County did report a higher fatality rate

946   for males than for females, and previous research investigating sex disparities also found that

947   while males are not more likely to test positive, they are more likely to be hospitalized or die

948   from COVID-19 (50). We have no information on whether any of the participants testing positive

949   through the EXCITE lab were hospitalized.

950   Adults 19+ were overall more likely to test positive than younger age groups ($p <$

951   0.0001), partly because the majority of the participants were adults from UCSD (Table 7). While

952   almost all UCSD participants were aged 19+, the average age of people testing positive at

953   UCSD was slightly lower than those testing negative (25.2 vs. 26.4, respectively; $p = 0.002$). For

954   private school participants, we found that students tested positive less frequently than adults,

955   but this trend was not extended to public school participants. At private schools, adults were

956   more likely to test positive than children (2.3% of adults as compared to 1.0% of children, $p =$

957   0.002), but at public schools, children aged 11-13 were the most likely to test positive ($p =$ 0.04).

958   This could be due to differences in testing uptake by the schools: for most private schools,

959   students and staff who attended in-person learning at school were required to participate in

960   regular testing, but for public schools, participation was voluntary. This testing program was

961   designed for asymptomatic screening, and participants who felt sick were discouraged from

962   coming to school and were encouraged to seek testing from SD County testing sites or primary

963   care providers. Therefore, these data do not show the complete picture, but they do show that

964   with proper protective measures, students attending in-person schooling are not testing positive

965   more frequently than the general population (Fig 3), and in the case of the private schools in this

966   study, may be testing positive less frequently than adults in the same settings. Our private

967   school results are similar to other studies, which have also shown that transmission rates in

968   schools are low (5,6), and that students were less likely to test positive than staff in educational

969   settings (8). Also of note, there were no outbreaks in participating schools in this study that were

970   attributable to in-school transmission. The low positivity among school-aged children provides

971   an argument for opening P-12 schools for in-person learning; with teachers and some school-

972   aged children eligible for vaccination across the US, and children representing the age group

973   that is currently least likely to test positive, our study and others suggest that schools can re-

974   open with minimal risk of community transmission (5–8). However, it should be noted that the

975   low rate of positivity among children observed at the County level (Fig 2) could be a result of

976   school closures during this time, which would have drastically reduced the number of contacts

977   each child would have.

978

Fig 8. Age and sex distribution of (A) all EXCITE UCSD/school participants, and (B) all COVID-19 positive participants from the same population. The dotted line in each plot represents the median age.

A large proportion of participants chose not to identify their race (39.9%) or ethnicity (60.9%) (Table 7). Across all three populations studied, approximately 40% of participants did not report their race, but the reporting of ethnicity varied by population: two-thirds (67%) of UCSD participants did not report their ethnicity, compared to ~40% of private school participants and just ~20% of public school participants. Because UCSD student/employee records default to unspecified race and ethnicity unless a participant changes their status themselves, or their status is changed by a healthcare worker during a medical visit, this could account for a significant proportion of the participants who did not report a race or ethnicity. However, the discrepancy between race reporting and ethnicity reporting at UCSD suggests that there is a portion of this population reporting race, but declining to report ethnicity. Similar proportions of

45

994 participants did not report their race at both public and private schools, but twice as many

995 private school participants (proportionally) declined to report their ethnicity. As with the

996 SEARCH study, legal status in the US was not a requirement for participation in the EXCITE

997 testing program, nor was it a question asked of potential participants.

998   More UCSD participants identified as Asian (22.4%, as compared to 7.6% and 4.1% for

999 private and public schools, respectively), while more P-12 school participants identified as White

1000 (44.9% and 46.7% for private and public schools, respectively, as compared to 22.9% for

1001 UCSD). While the overall number of participants identifying as Black/African American,

1002 Indigenous/Native American, or Pacific Islander was comparatively low, more public school

1003 participants selected these options as their race identity (Table 7). Additionally, approximately

1004 half of public school participants identified as Hispanic, compared to just 6.8% of UCSD and

1005 private school participants (Table 7). Overall, participants identifying as Black/African American

1006 or Other/Mixed Race were more likely to have a positive test, as well as those with an

1007 unspecified race ($p < 0.0001$), although when separated by group the result was not statistically

1008 significant for P-12 schools. Additionally, participants identifying as Hispanic were also more

1009 likely to test positive, although this difference was only statistically significant for UCSD

1010 participants ($p < 0.0001$), not for P-12 schools. Even though the result was not statistically

1011 significant, there was a trend toward a larger proportion of Black/African American and Hispanic

1012 participants from the public schools testing positive for COVID-19 (Table 7). Similar racial and

1013 ethnic disparities have been noted previously by other researchers, highlighting the

1014 disproportionate toll the COVID-19 pandemic has had on already-marginalized population in the

1015 US (51–55). In particular, Gil et al. (51) identified potential reasons why Hispanic people may

1016 test positive for COVID-19 more frequently, including: higher rates of coexisting medical

1017 conditions; lower rates of health insurance; immigration status; and language barriers. Similarly,

1018 Millett et al. (54) note that counties with a larger Black population were also more likely to have

1019 higher rates of air pollution, comorbidities, and lower rates of health insurance. Factors such as

1020   language barriers and lack of health insurance prevent access to testing or hospital care, while

1021   factors such as air pollution and comorbidities can increase the severity of an infection.

1022 **Table 7.** Demographic information of EXCITE participants. The Positive column includes individuals who tested positive for COVID-
1023 19 at least once, while the Negative column includes individuals who never tested positive. Chi-square and *t*-tests were performed to
1024 test for differences among groups. Differences were considered significant at *p* ≤ 0.05 and are indicated in bold. The first column
1025 (Total) was not included in statistical analysis and was included to show the demographics of the entire population, regardless of test
1026 result.

	Total	Overall			UCSD			Public Schools			Private Schools		
		Positive	Negative	*p*-value	Positive	Negative	*p*-value	Positive	Negative	*p*-value	Positive	Negative	*p*-value
Age, mean (SD), median	25.1 (11.9) 22	24.8 (10.9) 22	25.2 (11.9) 22	0.95	25.2 (9.1) 22	26.4 (10.1) 22	**0.002**	18.1 (16.3) 11	21.8 (18.9) 11	0.63	25.1 (17.8) 18	20.7 (15.3) 16	**0.05**
Age group, n (%)													
2-10	1497 (5.5)	30 (2.0)	1467 (98.0)	< 0.0001	--	--	1.00	17 (3.1)	535 (96.9)	**0.04**	13 (1.4)	932 (98.6)	**0.002**
11-13	814 (3.0)	18 (2.2)	796 (97.8)		--	--		**11 (6.4)**	162 (93.6)		7 (1.1)	634 (98.9)	
14-18	1989 (7.3)	15 (0.8)	1974 (99.2)		1 (1.7)	57 (98.3)		0 (0.0)	32 (100.0)		14 (0.7)	1885 (99.3)	
19+	22829 (84.2)	**597 (2.6)**	22232 (97.4)		558 (2.6)	20574 (97.4)		10 (2.2)	445 (97.8)		**29 (2.3)**	1213 (97.7)	
Race, n (%)													
Unspecified	10866 (39.9)	**294 (2.7)**	10572 (97.3)		**253 (2.9)**	8329 (97.1)		17 (3.2)	519 (96.8)		24 (1.4)	1724 (98.6)	
White	7601 (27.9)	149 (2.0)	7452 (98.0)		102 (2.1)	4766 (97.9)		17 (2.8)	581 (97.2)		30 (1.4)	2105 (98.6)	
Black/AA	497 (1.8)	**14 (2.8)**	483 (97.2)	< 0.0001	9 (2.6)	339 (97.4)	< 0.0001	5 (8.5)	54 (91.5)	0.35	0 (0.0)	90 (100.0)	0.54
Other/mixed	2940 (10.8)	**109 (3.7)**	2831 (96.3)		**103 (4.0)**	2454 (96.0)		--	--		6 (1.6)	377 (98.4)	
Asian	5166 (19.0)	96 (1.9)	5070 (98.1)		91 (1.9)	4659 (98.1)		1 (1.9)	52 (98.1)		4 (1.1)	359 (98.9)	
Indigenous/NA	108 (0.4)	2 (1.8)	106 (98.2)		1 (1.4)	70 (98.6)		0 (0.0)	19 (100.0)		1 (5.6)	17 (98.4)	
Pacific Islander	74 (0.3)	0 (0.0)	74 (100.0)		0 (0.0)	45 (100.0)		0 (0.0)	16 (100.0)		0 (0.0)	13 (100.0)	
Ethnicity, n (%)													
Unspecified	16601 (60.9)	403 (2.4)	16198 (97.6)	< 0.0001	372 (2.6)	14100 (97.4)	< 0.0001	8 (2.8)	278 (97.2)	0.35	23 (1.3)	1820 (98.7)	0.13
Hispanic	2398 (8.8)	**103 (4.3)**	2295 (95.7)		**71 (4.9)**	1376 (95.1)		24 (3.8)	606 (96.2)		8 (2.5)	313 (97.5)	
Non-Hispanic	8253 (30.3)	158 (1.9)	8095 (98.1)		116 (2.2)	5186 (97.8)		8 (2.2)	357 (97.8)		34 (1.3)	2552 (98.7)	
Sex, n (%)													
Female	13367 (49.1)	336 (2.5)	13031 (97.5)	0.50	279 (2.7)	9904 (97.3)	0.65	20 (2.8)	688 (97.2)	0.33	37 (1.5)	2439 (98.5)	0.73
Male	13332 (48.9)	318 (2.4)	13014 (97.6)		276 (2.5)	10597 (97.5)		17 (4.1)	399 (95.9)		25 (1.2)	2018 (98.8)	
Other/unspecified	553 (2.0)	10 (1.8)	543 (98.2)		4 (2.4)	161 (97.6)		3 (1.9)	154 (98.1)		3 (1.3)	228 (98.7)	

1027

48

1028   Participant-provided zip codes of residence were overlaid on a map of SD County (Fig

1029   9). Participants involved in testing through the EXCITE lab came from all across SD County. For

1030   P-12 schools, testing was conducted on-site at each school, and for UCSD participants, testing

1031   was conducted on campus. Participant density was highest in regions surrounding UCSD in La

1032   Jolla, with densely tested regions extending north and south along the coast away from UCSD,

1033   and decreasing in density when moving inland and when approaching the US-Mexico border

1034   (Fig 9a). Interestingly, participants who tested positive did not necessarily follow the same

1035   density pattern as overall testing (Fig 9b). The highest density of positive participants was

1036   located around UCSD, which was expected given the large proportion of on-campus students

1037   participating in testing through the EXCITE lab. Apart from the UCSD campus, the areas with

1038   the highest proportion of positive participants included San Diego, National City, and Chula

1039   Vista, all located south of UCSD. Areas such as Encinitas and Solana Beach, to the north of

1040   UCSD, were heavily tested, but represented a disproportionately small portion of positive

1041   participants. Conversely, Chula Vista was not heavily tested, but represented a

1042   disproportionately large portion of positive participants. There are many possible explanations

1043   for this discrepancy. Median household income (2019) in Encinitas and Chula Vista was

1044 $116,022 and $81,272, respectively (https://www.census.gov/). A previous study found that a

1045   decrease of $10,000 median household income in New York City was correlated with a 1.6%

1046   increase in COVID-19 positivity rate (55). If this correlation is applied to San Diego County, we

1047   would expect positivity rates to be approximately 5.4% higher in Chula Vista as compared to

1048   Encinitas. This same study found an increase in COVID-19 positivity in more densely populated

1049   areas (55); these areas are more likely to have multi-family housing such as apartment

1050   buildings, where physical distancing is more challenging. In Encinitas, population density in

1051   2010 was 3,164 people per square mile, while in Chula Vista, population density was 4,915/sq

1052   mi (https://www.census.gov/). Chula Vista also has significantly more Black/African American

1053   and Hispanic residents as compared to Encinitas, and both of these communities have been

1054   identified by previous studies as being at higher risk for COVID-19, as discussed above.

1055   (A)

1056
1057   (B)

1058
1059   **Fig 9.** Zip codes of residence of (A) all UCSD/P-12 school participants tested through the
1060   EXCITE lab, and (B) UCSD/P-12 school participants who tested positive for COVID-19 through

the EXCITE lab. The deepness of color is proportionate to the number of participants who chose
that zip code as their area of residence. Zip codes from outside of San Diego County were
assumed to belong to UCSD students living on-campus who provided their home address, and
were re-assigned as such. The icon on both images represents the location of the UCSD
campus.

Return to Learn at UCSD

During the fall 2020 quarter, UCSD housed 9,129 on-campus students, and COVID-19

testing on a bi-weekly basis was mandatory for any students who lived in campus owned

housing or came to campus for classes. Student athletes were tested weekly when training, and

more often when competing. During the fall quarter, 6% of classes were taught in-person, with a

maximum in-person class size of 50, but this was reduced to 2% of classes in-person mid-

quarter as SD County restrictions on indoor teaching were implemented. Following County

restrictions on indoor teaching, all in-person classes were moved to outdoor settings, with large

tents acting as outdoor classrooms. Testing was provided free-of-charge to students, faculty,

and staff, and while testing was not mandatory for faculty and staff, it was recommended. High-

volume testing sites for students moving on-campus were set up at the beginning of each

quarter, and student move-in was staggered to allow for adequate testing and social distancing.

Testing at term start among students moving/returning to campus-owned housing was provided

at days 1 and 10 in the fall quarter. Sequestration (masking in all areas including in residences

with the exception of when inside a single bedroom or bathroom) was implemented during the

move in testing period.

Students living on-campus who tested positive at term start or at any point thereafter

were given options on how to self-isolate for the required 14 days before being allowed to move

into/return to their residential suites. Many students availed themselves of the temporary

isolation housing that was provided on campus, while others chose to return home to isolate,

and some, mainly graduate students, chose to isolate in their campus residence with their

1088   families or alone (this option was not presented to students living in shared housing). Students

1089   living off-campus who tested positive could remain in their homes if they could effectively isolate

1090   themselves from others, or were provided isolation housing on campus if desired.

1091   Masking was required in all public spaces on campus, both indoors and outdoors, and

1092   beginning mid-way through the fall quarter, students were allowed to gather in groups of three

1093   for up to two hours at a time, provided everyone was outdoors, masked, and socially distanced.

1094   At certain points throughout the quarter, cases rose and students were required to sequester

1095   temporarily. Bi-weekly asymptomatic testing was accomplished via the installation of vending

1096   machines throughout campus that supplied COVID-19 testing kits containing a collection tube

1097   pre-filled with media, a swab, and instructions on how to self-collect, as well as drop-off bins,

1098   from which samples were collected multiple times per day for processing by the EXCITE lab. If

1099   at any point a student developed symptoms characteristic of COVID-19, they were tested via

1100   the CALM lab on campus and asked to self-isolate until their test results were returned.

1101   Integration of the testing program with two smartphone applications - the UCSD

1102   student/employee app and the UCSD Health EPIC Electronic Health Record MyChart app -

1103   allowed for an easy method for linking test tube barcodes with student/employee ID numbers,

1104   and provided students and employees with their test results, whether they were negative or

1105   positive. Individuals with positive test results also received a telephone call from a clinical

1106   provider at UCSD Health, and were contacted daily during the isolation period. Most results

1107   were returned the day after sample collection. We believe this combination of quick turnaround

1108   time and the return of results for every sample increased compliance, because it provided

1109   continuous feedback to students and employees.

1110   The number of students residing on campus decreased after the Thanksgiving 2020

1111   weekend, because students who left for the holiday were incentivized (with partial refunds of

1112   housing costs) to remain at home until the winter quarter started in January 2021. This measure

1113   aimed to reduce an influx of new COVID-19 cases from students who gathered with other

1114   households over the Thanksgiving weekend. Students returning to campus from fall break were

1115   tested at days 1, 5, and 10 after return. Between Thanksgiving and the beginning of the winter

1116   quarter, weekly testing was encouraged but not mandatory, while bi-weekly testing remained

1117   mandatory.

1118   When the winter quarter began in early January 2021, student move-in was again

1119   staggered to allow for all students to get tested and to prevent crowding; students were also

1120   asked to test themselves on days 1, 3, and 5 after move-in, after which time weekly testing was

1121   mandatory for those residing in campus owned housing or coming to campus. During the winter

1122   quarter, UCSD housed 8700 on-campus students who were required to test weekly, in addition

1123   to 1850 off-campus students who came to campus for classes, not including student athletes

1124   who came to campus for training and were required to test more frequently. During the winter

1125   quarter, 2% of classes were taught in-person, all of which were taught in an outdoor classroom

1126   setting. In addition to asymptomatic screening by the EXCITE lab, UCSD also offered

1127   symptomatic and exposure testing via the CALM lab. Together, the EXCITE and CALM labs

1128   made up the entirety of COVID-19 testing conducted on-campus at UCSD. Testing data from

1129   the CALM lab were not included in this study.

1130   **Return to Learn at Preschool-Grade 12 Schools**

1131   The EXCITE lab collaborated with 11 private schools and a group of 13 public schools in

1132   SD County to provide repeated screening of students, teachers, and staff. These schools

1133   offered different in-person learning schedules, with some offering in-person learning five days a

1134   week and others alternating between in-person and remote learning, with a portion of students

1135   attending in-person learning on different days. During the timeframe this study took place, the

1136   large majority of public schools in SD County were fully remote. However, some schools were

1137   allowed to remain open for in-person learning on a limited basis, based on the CDC's social

1138   vulnerability index and the California Department of Public Health's (CDPH) Healthy Places

1139   Index (HPI). Public schools that were in the lowest HPI quartile were selected, as they

1140   represented students from low socio-economic status communities, including many immigrant,

1141   refugee, and other socially vulnerable communities. Not all students from these communities

1142   participated in on-site learning; schools offered this choice to children who were struggling with

1143   remote learning due to their housing situation (homelessness, overcrowded housing, poor wifi)

1144   and/or those who were struggling academically. For public schools, testing was offered weekly

1145   but was not mandatory, and compliance was lower for students than for staff at these schools,

1146   with an average of 68% of students and 92% of staff who consented to testing. For most private

1147   schools, testing was mandatory in order to attend in-person learning, but remote learning was

1148   also available to students. The testing schedule varied for each private school, from weekly

1149   testing to exposure-based testing, but most schools required students and staff to provide a

1150   negative test before returning to school after breaks and holidays (Table S5). Schools used a

1151   variety of safety and risk mitigation measures to attempt to ensure the health of those

1152   participating in in-person learning. We were provided general information for the public schools,

1153   and more specific information for most participating private schools, detailed in Table S5 and

1154   summarized below.

1155   At the private schools for which we obtained details of their risk mitigation strategies,

1156   cohort size ranged from 9-14 students up to the entire grade level. For at least one private

1157   school, a single positive test within a cohort meant that the entire cohort stayed at home for

1158   remote learning for two weeks, and contact tracing was used to determine any possible

1159   exposures outside the cohort. Because this method was quite disruptive for the students,

1160   administrative staff at this school recommend creating smaller cohort sizes. Desks in

1161   classrooms were placed at a distance of 4-6 ft (1.2-1.8 m), and while the established

1162   recommended distance is 6 ft (1.5 m), a recent report that has been adopted by the CDC

1163   suggests that a 3 ft (0.9 m) spacing may be just as effective at preventing the spread of SARS-

1164   CoV-2, as long as everyone is masked (56). Masking was required at all times, with exceptions

54

1165   for very young children and when eating (physically distanced, outside) and napping (for young

1166   children). For most schools, indoor classrooms were either retrofitted with portable home-made

1167   HEPA air filtration systems or had upgraded HVAC systems installed with higher-quality air

1168   filters. Different schools employed different indoor/outdoor instruction methods, with some

1169   schools teaching exclusively indoors, some teaching almost exclusively in outdoor classrooms,

1170   and others using a combination, emphasizing mandatory time outdoors. We note that outdoor

1171   instruction or mandatory outdoor time may not be feasible everywhere, especially in the winter

1172   months. One private school described one-way walking traffic set up throughout the campus, as

1173   well as staggering student drop-off and pick-up to prevent crowding. Different schools used

1174   different methods of contact tracing and daily symptom checking, and all six private schools that

1175   provided details of their symptom screening policies mentioned using dedicated applications,

1176   including Emocha, SchoolPass, and ProCare. These schools also implemented temperature

1177   checks upon arrival on campus. At the presence of any symptoms of illness, students and staff

1178   were required to switch to remote teaching until symptoms resolved.

1179   At the public schools, the following extra measures were taken to ensure the health and

1180   safety of students and staff, following CDC and CDPH guidance: mandatory masking for

1181   students and staff; grouping students into cohorts to minimize interactions; 6 ft (1.5 m) distance

1182   between desks; scheduled drop-off and pick-up times; heightened ventilation in classrooms;

1183   increased sanitization and hand-washing protocols; daily symptom checks and mandatory two-

1184   week at-home quarantines for students who present symptoms of illness; restricting

1185   parents/guardians and volunteers from campus; restricting the sharing of materials between

1186   students. For most of the public schools, a single positive test within a cohort resulted in the

1187   entire cohort returning to remote learning for two weeks.

1188

1189

Conclusions

1190

1191   In this study, we developed a high-throughput semi-automated pipeline for RT-qPCR

1192   detection of SARS-CoV-2, with scalable capacity and rapid turnaround times that was used for

1193   large-scale repeated asymptomatic screening on an individual basis. This pipeline was first

1194   used to test more than 6,000 healthcare workers and first responders in San Diego, California in

1195   the spring of 2020. The pipeline was then modified in the fall of 2020 and used to establish a

1196   dedicated CLIA-certified COVID-19 testing lab at the University of California, San Diego,

1197   allowing students and staff to return to campus safely by providing repeated asymptomatic

1198   screening. Testing was expanded to include firefighters and some preschool-grade 12 schools

1199   across San Diego County. Thus far, we have tested more than 150,000 nasal swabs from over

1200   28,000 individuals. More than half of participants who tested positive reported no symptoms at

1201   the time of testing, highlighting the importance of asymptomatic/pre-symptomatic screening. The

1202   presence of symptoms was significantly correlated with higher viral load. Hispanic and

1203   Black/African American participants from UCSD and partnering schools were more likely to test

1204   positive, highlighting the disproportionate toll the COVID-19 pandemic has had on already-

1205   marginalized populations within the US. At UCSD and at public schools, students were more

1206   likely to test positive for COVID-19 than staff. However, in private schools, students were less

1207   likely to test positive than staff. No correlation between age/sex and viral load was observed.

1208   We note that the results reported here were obtained during a time period (April 17, 2020 to

1209   February 5, 2021) when COVID-19 vaccination rates in San Diego were less than 10%. Our

1210   results suggest that schools ranging from preschool to university may be opened safely, even

1211   without vaccination, when proper health and safety measures are implemented, such mandatory

1212   masking, increased desk spacing, reduced cohort size, and repeat testing.

1213

1214

Acknowledgements

Funding

1238   no role in study design, data collection and analysis, decision to publish, or preparation of the

1239   manuscript.

Competing Interests

1241   Anterior nares swab samples for clinical validation of the Expedited COVID-19 Identification

1242   Environment (EXCITE) Laboratory Developed Tests (LDT) were donated by Helix Opco, LLC.

1243   We disclose that Dr. Laurent's spouse is an employee of Helix Opco, LLC.

1244

References

1246   1.   Roser M, Ritchie H, Ortiz-Ospina E, Hasell J. Coronavirus Pandemic (COVID-19)
1247   [Internet]. Our World In Data. 2020 [cited 2020 Jul 7]. Available from:
1248   https://ourworldindata.org/coronavirus
1249   2.   Sen S, Karaca-Mandic P, Georgiou A. Association of stay-at-home orders with COVID-19
1250   hospitalization in 4 states. J Am Med Assoc. 2020;323(24):2522–3.
1251   3.   Juneau CE, Pueyo T, Bell M, Gee G, Collazzo P, Potvin L. Evidence-based, cost-
1252   effective interventions to suppress the COVID-19 pandemic: A systematic review.
1253   medRxiv. 2020;1–27.
1254   4.   Fowler JH, Hill SJ, Levin R, Obradovich N. The effect of stay-at-home orders on COVID-
1255   19 cases and fatalities in the United States. arXiv. 2020;1–16.
1256   5.   Dawson P, Worrell MC, Malone S, Tinker SC, Fritz S, Maricque B, et al. Pilot
1257   Investigation of SARS-CoV-2 Secondary Transmission in Kindergarten Through Grade
1258   12 Schools Implementing Mitigation Strategies — St. Louis County and City of
1259   Springfield, Missouri, December 2020. Morb Mortal Wkly Rep. 2021;70(12):449–55.
1260   6.   Macartney K, Quinn HE, Pillsbury AJ, Koirala A, Deng L, Winkler N, et al. Transmission of
1261   SARS-CoV-2 in Australian educational settings: a prospective cohort study. Lancet Child
1262   Adolesc Heal. 2020;4:807–16.
1263   7.   Panovska-Griffiths J, Kerr CC, Stuart RM, Mistry D, Klein DJ, Viner RM, et al.
1264   Determining the optimal strategy for reopening schools, the impact of test and trace
1265   interventions, and the risk of occurrence of a second COVID-19 epidemic wave in the UK:
1266   a modelling study. Lancet Child Adolesc Heal. 2020;4:817–27.
1267   8.   Ladhani SN, Baawuah F, Beckmann J, Okike IO, Ahmad S, Garstang J, et al. SARS-
1268   CoV-2 infection and transmission in primary schools in England in June-December, 2020
1269   (sKIDs): an active, prospective surveillance study. Lancet Child Adolesc Heal [Internet].
1270   2021;1–11. Available from: https://doi.org/10.1016/S2352-4642(21)00061-4
1271   9.   Gandhi M, Yokoe DS, Havlir D V. Asymptomatic Transmission, the Achilles' heel of
1272   current strategies to control Covid-19. N Engl J Med. 2020;382(22):2158–60.
1273   10.   Benefield AE, Skrip LA, Clement A, Althouse RA, Chang S, Althouse BM. SARS-CoV-2
1274   viral load peaks prior to symptom onset: a systematic review and individual-pooled
1275   analysis of coronavirus viral load from 66 studies. medRxiv. 2020;1–23.
1276   11.   Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection. Ann Intern Med.
1277   2020;1–7.
1278   12.   Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL, et
1279   al. Spread of SARS-CoV-2 in the Icelandic population. N Engl J Med.

1280   2020;382(24):2302–15.

1281 13. Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio C, et
1282   al. Suppression of COVID-19 outbreak in the municipality of Vo, Italy. medRxiv [Internet].
1283   2020;1–23. Available from:
1284   https://www.medrxiv.org/content/10.1101/2020.04.17.20053157v1

1285 14. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al.
1286   Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. N
1287   Engl J Med. 2020;382(22):2081–90.

1288 15. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al.
1289   Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. N Engl
1290   J Med. 2020;382(10):970–1.

1291 16. Daley P, Castriciano S, Chernesky M, Smieja M. Comparison of flocked and rayon swabs
1292   for collection of respiratory epithelial cells from uninfected volunteers and symptomatic
1293   patients. J Clin Microbiol. 2006;44(6):2265–7.

1294 17. Ryan J, Coufal N, Aronson S, Ladt K, Andersen C, Zeller M, et al. 3D printed
1295   nasopharyngeal swabs with wrapped rayon fibers developed and validated by SCREEN
1296   (San Diego Covid 19 Research Enterprise Network) [Internet]. Protocols.io. 2020. p. 1–9.
1297   Available from: https://dx.doi.org/10.17504/protocols.io.bemxjc7n

1298 18. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
1299   data capture (REDCap) - A metadata-driven methodology and workflow process for
1300   providing translational research informatics support. J Biomed Inform. 2009;42(2):377–
1301   81.

1302 19. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap
1303   Consortium: building an international community of software platform partners. J Biomed
1304   Inform. 2019;95:103208.

1305 20. Sathe S, Mah C, Ahmed N, Ragsac MF, Williams J, Yeo G. INSPECT sample tracking
1306   system [Internet]. protocols.io. 2020 [cited 2021 May 26]. p. 1–8. Available from:
1307   https://www.protocols.io/view/inspect-sample-tracking-system-bis8kehw

1308 21. Marotz L, Belda-Ferre P, Zeller M, Anderson C, Morgan SC, Knight R, et al. Semi-
1309   Automated Extraction of Viral RNA using the Omega Bio-tek Mag-Bind Viral DNA / RNA
1310   96 Kit for SARS- CoV-2 Detection [Internet]. protocols.io. 2021 [cited 2021 May 26]. p. 1–
1311   15. Available from: dx.doi.org/10.17504/protocols.io.brqhm5t6

1312 22. De Hoff P, Morgan SC, Laurent LC. Semi-Automated and Miniaturized SARS-CoV-2
1313   Detection using TaqPath COVID-19 Multiplex Real-Time RT-PCR Assay [Internet].
1314   protocols.io. 2021 [cited 2021 May 26]. p. 1–14. Available from:
1315   dx.doi.org/10.17504/protocols.io.brhvm366

1316 23. Belda-Ferre P, Marotz L, Humphrey G, Morgan SC, Knight R. Semi-Automated Extraction
1317   of Viral RNA using the MagMax Viral Pathogen (MVPII) 96 Kit for SARS-CoV-2
1318   Detection [Internet]. protocols.io. 2021 [cited 2021 May 26]. p. 1–15. Available from:
1319   dx.doi.org/10.17504/protocols.io.brcvm2w6

1320 24. Wickham H, Averick M, Bryan J, Chang W, McGowan LD, François R, et al. Welcome to
1321   the Tidyverse. J Open Source Softw. 2019;4(43):1686.

1322 25. Grolemund G, Wickham H. Dates and times made easy with lubridate. J Stat Softw.
1323   2011;40(3):1–25.

1324 26. Patil I. Visualizations with statistical details: the "ggstatsplot" approach. J Open Source
1325   Softw. 2021;6(59):1–10.

1326 27. Specht I, Sani K, Botti-Lodovico Y, Hughes M, Heumann K, Bronson A, et al. The Case
1327   for Altruism in Institutional Diagnostic Testing. medRxiv [Internet]. 2021;1–18. Available
1328   from: http://medrxiv.org/content/early/2021/03/25/2021.03.16.21253669.abstract

1329 28. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA
1330   Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021;1–12.

29. Dean N. Hospital admissions due to COVID-19 in Scotland after one dose of vaccine. Lancet. 2021;397:1601–3.

30. Baggio S, L'Huillier AG, Yerly S, Bellon M, Wagner N, Rohr M, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load in the Upper Respiratory Tract of Children and Adults With Early Acute Coronavirus Disease 2019 (COVID-19). Clin Infect Dis. 2020;1–3.

31. Jacot D, Greub G, Jaton K, Opota O. Viral load of SARS-CoV-2 across patients and compared to other respiratory viruses. Microbes Infect [Internet]. 2020;22(10):617–21. Available from: https://doi.org/10.1016/j.micinf.2020.08.004

32. Mahallawi WH, Alsamiri AD, Dabbour AF, Alsaeedi H, Al-Zalabani AH. Association of Viral Load in SARS-CoV-2 Patients With Age and Gender. Front Med. 2021;8:1–5.

33. Madera S, Crawford E, Langelier C, Tran NK, Thornborrow E, Miller S, et al. Nasopharyngeal SARS-CoV-2 viral loads in young children do not differ significantly from those in older children and adults. Sci Rep [Internet]. 2021;11(3044):1–4. Available from: https://doi.org/10.1038/s41598-021-81934-w

34. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20:565–74.

35. Hasanoglu I, Korukluoglu G, Asilturk D, Cosgun Y, Kalem AK, Altas AB, et al. Higher viral loads in asymptomatic COVID-19 patients might be the invisible part of the iceberg. Infection [Internet]. 2021;49:117–26. Available from: https://doi.org/10.1007/s15010-020-01548-8

36. Heald-Sargent T, Muller WJ, Zheng X, Rippe J, Patel AB, Kociolek LK. Age-related differences in nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) levels in patients with mild to moderate Coronavirus Disease 2019 (COVID-19). JAMA Pediatr. 2020;174(11):902–3.

37. Euser S, Aronson S, Manders I, Lelyveld S Van, Herpers B, Sinnige J, et al. SARS-CoV-2 viral load distribution reveals that viral loads increase with age: a retrospective cross-sectional cohort study. medRxiv [Internet]. 2021;1–25. Available from: https://doi.org/10.1101/2021.01.15.21249691

38. Washington NL, Gangavarapu K, Zeller M, Bolze A, Cirulli ET, Schiabor Barrett KM, et al. Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. med. 2021;1–19.

39. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. J Am Med Assoc. 2020;323(11):1061–9.

40. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.

41. Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, et al. Clinical progression of patients with COVID-19 in Shanghai, China. J Infect [Internet]. 2020;80:e1–6. Available from: https://doi.org/10.1016/j.jinf.2020.03.004

42. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state. J Am Med Assoc. 2020;323(16):1612–4.

43. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762–8.

44. Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan: A retrospective observational study. Am J Respir Crit Care Med. 2020;201(11):1372–9.

45. Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis [Internet]. 2020;20:656–7. Available from: http://dx.doi.org/10.1016/S1473-3099(20)30232-2

46. Wang Y, Zhang L, Sang L, Ye F, Ruan S, Zhong B, et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. J Clin Invest. 2020;130(10):5235–44.

47. Greene DN, Jackson ML, Hillyard DR, Delgado JC, Schmidt R. Decreasing median age of COVID-19 cases in the United States - changing epidemiology or changing surveillance? PLoS One [Internet]. 2020;15(10):e0240783. Available from: https://doi.org/10.1101/2020.07.22.20160119

48. Bwire GM. Coronavirus: Why men are more vulnerable to COVID-19 than women? SN Compr Clin Med. 2020;1–3.

49. Egede LE. Race, ethnicity, culture, and disparities in health care. J Gen Intern Med. 2006;21(6):667–9.

50. Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun [Internet]. 2020;11(6317):1–10. Available from: http://dx.doi.org/10.1038/s41467-020-19741-6

51. Gil RM, Marcelin JR, Zuniga-Blanco B, Marquez C, Mathew T, Piggott DA. COVID-19 pandemic: Disparate health impact on the Hispanic/Latinx population in the United States. J Infect Dis. 2020;222:1592–5.

52. Rodriguez-Diaz CE, Guilamo-Ramos V, Mena L, Hall E, Honermann B, Crowley JS, et al. Risk for COVID-19 infection and death among Latinos in the United States: examining heterogeneity in transmission dynamics. Ann Epidemiol [Internet]. 2020;52:1–10. Available from: https://doi.org/10.1016/j.annepidem.2020.07.007

53. DiMaggio C, Klein M, Berry C, Frangos S. Black/African American Communities are at highest risk of COVID-19: spatial modeling of New York City ZIP Code–level testing results. Ann Epidemiol [Internet]. 2020;51:7–13. Available from: https://doi.org/10.1016/j.annepidem.2020.08.012

54. Millett GA, Jones AT, Benkeser D, Baral S, Mercer L, Beyrer C, et al. Assessing differential impacts of COVID-19 on black communities. Ann Epidemiol [Internet]. 2020;47:37–44. Available from: https://doi.org/10.1016/j.annepidem.2020.05.003

55. Whittle RS, Diaz-Artiles A. An ecological study of socioeconomic predictors in detection of COVID-19 cases across neighborhoods in New York City. BMC Med. 2020;18(271):1–17.

56. van den Berg P, Schechter-Perkins EM, Jack RS, Epshtein I, Nelson R, Oster E, et al. Effectiveness of 3 versus 6 ft of physical distancing for controlling spread of Coronavirus Disease 2019 among primary and secondary students and staff: A retrospective, statewide cohort study. Clin Infect Dis. 2021;1–8.

61

Supplemental Figs

Fig S1. (A-C) RT-qPCR performance of miniaturized (3 µL) and full-scale (25 µL) reactions as compared to theoretical results, for three targeted regions of the SARS-CoV-2 genome: (A) N Gene; (B) S Gene; (C) ORF1ab. (D-F) RT-qPCR performance of different reactions (varied total reaction volume and RNA input volume) as compared to theoretical results, for three targeted regions of the SARS-CoV-2 genome: (A) N Gene; (B) S Gene; (C) ORF1ab. Every point in each graph represents the average of 3 technical replicates.

Fig S2. Limit of detection of SARS-CoV-2 viral RNA at different concentrations, with viral RNA spiked into negative NP control samples prior to RNA extraction. Each point represents a single replicate reaction.

Fig S3. Sample processing times for samples at the EXCITE lab (n = 144,971).
"Scan_to_processing" refers to the time from when a participant scans a tube barcode for self-collection to when the sample is received by the EXCITE lab and begins processing.
"Processing_to_submission" refers to the time it takes to process the sample by the EXCITE lab, from the time the sample is received to the time the result is returned.
"Scan_to_submission" refers to the sum of the two previous times, the total time it takes to

1454   receive results. Samples that were recorded as taking longer than five days to process were

1455   considered technical errors and were removed from this plot, along with samples with missing

1456   data for one or more of the timepoints.

1457

1458

1459

1460

1461   **Fig S4.** Viral load (estimated by average Ct value) of COVID-19 positive individuals, separated

1462   by age group. A Kruskal-Wallis test indicated no significant difference in viral load among age

1463   groups ($p = 0.78$).

1464

1465
1466 **Fig S5.** SARS-CoV-2 viral gene dropouts during RT-qPCR detection as a function of median
1467 viral load (Ct value).
1468
1469
1470

Fig S6. The number of times (A) SEARCH study participants and (B) EXCITE lab participants
chose to be tested for SARS-CoV-2. Healthcare workers from Scripps Health and Rady systems
were tested between April 17 and June 30, 2020 via the SEARCH study. Students, faculty, and
staff from the University of California, San Diego (UCSD) and from public and private schools in
San Diego County were tested between Sept 15, 2020 and February 5, 2021 via the EXCITE
lab. San Diego Fire-Rescue Department (SDFD) participants were tested via both the SEARCH
study and the EXCITE lab during the same timeframes.

Supplemental Tables

Table S1. Comparison of 3D-printed and commercially-sourced nasopharyngeal swabs. In total, 25 pediatric patients and nine adult patients were swabbed to perform the validation of the 3D-printed swabs. Of the 25 pediatric samples, 22 were tested using a viral respiratory panel, and three were tested using a COVID-19 test. All nine adult samples were COVID-19 positive; however, only four had both 3D-printed and commercial swabs.

	Commercial Swab	3D-Printed Swab
Pediatric		
Respiratory Viral Panel		
Negative	16/16 (100%)	16/16 (100%)
Positive (single)	3/5 (60%)	5/5 (100%)
Positive (multiple)	1/1 (100%)	1/1 (100%)
COVID-19 negative	2/2 (100%)	2/2 (100%)
COVID-19 positive	1/1 (100%)	1/1 (100%)
Adult		
COVID-19 positive (in parallel)	2/4 (50%)	4/4 (100%)
COVID-19 positive (3D swab only)	Not available	5/5 (100%)

Table S2. Technical validation of anterior nares swabs in different media for SARS-CoV-2 detection: PrimeStore® Molecular Transport Medium (MTM media/ANM sample type); Mawi DNA Technologies iSWAB Microbiome buffer (Mawi media/ANW sample type), and 5% sodium dodecyl sulfate (SDS media/AND sample type). Limit of detection for triplicate contrived samples containing different concentrations of viral particles (VP) per mL (250 - 32,000). Rows in bold indicate the limit of detection for that media type. Three SARS-CoV-2 viral genes were targeted for amplification (N gene, Orf1ab, and S gene), as well as an internal control (MS2). A minimum of 2/3 viral gene targets were required to amplify within each replicate to be considered a positive result.

		N Gene			Orf1ab			S Gene			MS2		
	VP/mL	1	2	3	1	2	3	1	2	3	1	2	3
ANM	32000	28.56724	27.30496	29.05796	28.123	26.74671	28.40087	28.23621	26.90927	28.74655	30.88804	30.39208	31.40189
	16000	28.59086	29.10027	30.37453	27.87927	28.2653	29.04837	28.28125	28.63926	30.22964	30.47556	30.3301	32.33632
	8000	29.622	29.6161	31.03946	28.8252	28.9988	30.13729	29.59232	29.40543	30.42216	30.80075	30.81684	32.18524
	4000	30.55292	29.34379	31.57382	29.06067	28.92757	30.08623	30.36565	30.0086	30.64664	30.94963	31.10299	32.24866
	2000	29.79179	30.78633	32.3596	29.65664	29.51823	30.53481	30.80253	30.60761	32.05163	30.91378	30.87834	32.21166
	1000	31.95534	31.63872	32.23191	30.48554	30.74818	31.60106	31.6986	30.66024	31.82981	31.09695	30.54766	31.51518
	500	**31.8007**	**32.17833**	**32.93955**	**31.25087**	**30.67037**		**31.43116**	**31.69549**	**32.06826**	**31.05981**	**31.16852**	**31.70178**
	250	32.91542	32.62193		31.56975	31.78306	32.0334	32.01559	31.93159		30.60415	30.89187	32.10643
ANW	32000	27.6949	27.62062	28.6829	26.75763	27.07014	27.86881	27.33813	27.60611	28.84602	29.7765	29.94439	30.21699
	16000	27.77016	27.98963	30.38937	27.51569	27.56042	28.88784	28.21654	28.12109	29.61706	30.10374	30.00491	30.40088
	8000	29.58683	28.77404	29.10565	28.46152	28.83664	28.64296	29.12567	29.02891	29.54257	30.49041	30.77581	30.56796
	4000	30.67838	30.55936	30.49048	28.79253	29.14261	29.4781	30.15295	29.68094	29.89257	30.60305	30.637	30.54589
	2000	30.89805	31.18324	32.13199	30.06639	29.95144	30.58552	31.16762	30.60806	31.78862	30.70745	30.53986	31.03023
	1000	30.69853	31.70212	33.70245	30.83089	31.16146	31.39502	31.41211	31.37258	32.74824	30.87244	30.66293	31.0696
	500	33.08861	32.74819	33.7467	31.24067	31.50742	32.27259	32.32956	31.97728	32.70442	30.81637	30.69168	31.30658
	250	**32.69856**		**33.85752**	**31.97604**	**31.24246**	**32.41334**	**31.77786**	**31.17495**		**30.5527**	**30.24898**	**30.31604**
AND	32000	26.56684	26.48251	26.43064	26.01545	25.92576	25.85998	26.34711	26.31556	26.20625	30.40321	30.30017	30.44547
	16000	27.63647	27.65226	27.66501	26.83035	26.90872	27.02284	27.21644	27.42337	27.63582	30.42951	30.16785	30.07215
	8000	28.48938	28.46131	28.30104	27.79799	27.74197	27.61454	27.76735	28.23767	27.80854	30.27699	30.45726	30.03353
	4000	28.95999	28.80925	28.81392	28.00529	28.47926	28.04047	28.37351	28.91348	28.77715	30.12698	30.34609	29.99662
	2000	30.77094	30.59611	29.90652	29.35722	29.33499	29.5718	29.733	29.9439	29.90099	30.43141	30.74416	30.84527
	1000	30.85673	30.78722	31.12153	29.11394	29.77203	29.98141	29.87768	29.8279	30.48528	30.46241	30.82404	30.39688
	500	31.41748	32.30139	31.82398	29.82488	30.51586	30.76725	30.77686	30.89876	30.61647	30.47791	30.87041	30.89983
	250	**32.77331**	**33.0288**	**32.94244**	**29.98244**	**30.56765**	**30.93435**	**31.60111**	**31.51474**	**31.75622**	**30.88731**	**30.77039**	**30.52082**

504 **Table S3.** Technical validation of anterior nares swabs in different media for SARS-CoV-2 detection: PrimeStore® Molecular Transport Medium
505 (MTM media/ANM sample type); Mawi DNA Technologies iSWAB Microbiome buffer (Mawi media/ANW sample type), and 5% sodium dodecyl
506 sulfate (SDS media/AND sample type). A minimum of 20 contrived samples all containing the same concentration of viral particles (1000 VP/mL)
507 were tested for each media type. Three SARS-CoV-2 viral genes were targeted for amplification (N gene, Orf1ab, and S gene), as well as an
508 internal control (MS2). A minimum of 2/3 viral gene targets were required to amplify within each replicate to be considered a positive result, and a
509 minimum of 19/20 samples were required to return a positive result for this technical validation step.

	ANM				ANW				AND			
	N Gene	Orf1ab	S Gene	MS2	N Gene	Orf1ab	S Gene	MS2	N Gene	Orf1ab	S Gene	MS2
Replicate 1	33.20503	31.2742	33.32748	32.13901	32.328	29.96588	31.68405	30.2813	30.36313	28.84117	29.74154	29.97011
Replicate 2	33.11781	31.22991	31.90709	31.49288	32.665	30.83412	32.83377	30.47811	30.81601	30.43513	30.74937	30.34116
Replicate 3	32.15603	30.20218	31.47673	31.44101	33.419	30.95764	31.92202	30.8268	31.02649	30.16447	30.39575	30.27942
Replicate 4	32.12903	30.85151	31.2922	31.45474	33.009	30.14325	31.71588	30.55374	31.50233	30.96156	30.56672	30.63448
Replicate 5	32.66456	30.69429	31.49954	31.66452	33.065	30.48087	32.26574	30.59831	30.90308	29.73466	29.95023	29.85332
Replicate 6		30.76613	31.83545	31.09046			32.32624	30.43625	30.81576	29.68443	29.94711	29.85306
Replicate 7	31.54116	30.99806	30.75484	31.44883	31.949	30.05961	31.15406	30.01067	31.22313	28.91922	29.96547	30.3383
Replicate 8	31.26402	30.47032	30.82045	31.08399	30.934	30.81955	30.36134	29.98146	31.09156	29.31754	30.72157	30.03009
Replicate 9	31.64176	30.93807	30.8849	30.83263	31.736	31.03576	31.92403	30.77339	31.06431	30.29006	30.41665	30.08424
Replicate 10	32.00396	31.02591	31.52836	31.55012	33.078	30.57624	31.86759	30.87953	30.85805	30.70002	30.23393	30.21832
Replicate 11	32.84344	30.4075	31.35707	31.26224	33.776	30.80046	31.88817	30.70583	30.83426	30.12243	30.41913	30.12273
Replicate 12	31.63306	30.15641	31.23138	31.56804	32.900	30.88295	31.94054	31.03309	31.44029	30.38277	30.81528	30.20662
Replicate 13	31.4435	30.99032	30.90512	31.36599	32.569	30.44113	32.60187	30.92437	30.65612	30.03494	29.91626	29.9131
Replicate 14	31.06826	30.82614	30.56917	30.77931	33.554	31.75565	32.11547	30.57389	30.29833	29.73377	29.77454	29.81347
Replicate 15	31.12846	30.33739	30.75388	30.90927	31.823	30.77881	30.93723	30.43053	31.29008	28.71616	30.271	29.92114
Replicate 16	32.10682	30.81051	31.40603	30.78367	33.312	30.96995	31.25103	30.42333	30.91602	29.76852	29.95509	31.00376
Replicate 17	31.30213	30.68539	31.46759	30.47551	32.177	30.40417	32.03503	31.32467	30.81853	30.25693	30.90988	30.38307
Replicate 18	31.28477	30.36862	30.79565	30.63984	32.393	30.88316	31.48466	31.36795	30.81384	29.5703	30.3437	30.28908
Replicate 19	31.48638	30.27696	30.66186	30.81963	32.470	30.78672	31.53987	31.22123	30.9675	30.30584	30.77847	29.92241
Replicate 20	30.9396	30.73603		30.78493	32.968	30.75034	31.76518	31.39022	30.77984	29.19349	30.61045	30.16572
Replicate 21	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	31.18732	30.29526	30.71653	30.28227
Replicate 22	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	31.24267	30.011	30.23237	30.0241

510
511
512
513

514 **Table S4.** Clinical validation of anterior nares swabs in different media for SARS-CoV-2 detection: PrimeStore® Molecular Transport Medium (MTM
515 media/ANM sample type); Mawi DNA Technologies iSWAB Microbiome buffer (Mawi media/ANW sample type), and 5% sodium dodecyl sulfate
516 (SDS media/AND sample type). A minimum of 30 positive and 30 negative clinical samples were tested for each media type. Clinical validation
517 involved testing each sample twice, once using the experimental test to be validated and once with an FDA Emergency Use Authorization (EUA)
518 validated comparator. For ANM validation, the comparator was an EUA-authorized test developed by Helix LLC that also used MTM media; for
519 ANW and AND validation, the newly-validated ANM test was used as the comparator. Three SARS-CoV-2 viral genes were targeted for
520 amplification (N gene, Orf1ab, and S gene), as well as an internal control (MS2). A minimum of 2/3 viral gene targets were required to amplify within
521 each replicate to be considered a positive result, and a minimum 90% sensitivity/specificity (positive/negative agreement between samples tested
522 with the experimental and comparator tests, respectively) was required for clinical validation. Numbers in brackets represent 95% confidence
523 intervals.

	ANM		ANW		AND	
	Positive	**Negative**	**Positive**	**Negative**	**Positive**	**Negative**
Comparator Positive	30	0	32	0	35	2
Comparator Negative	0	32	0	54	0	54
Sensitivity	100% (88.43 - 100)		100% (89.11 - 100)		94.59% (81.81 - 99.34)	
Specificity	100% (89.11 - 100)		100% (93.40 - 100)		100% (93.40 - 100)	
Accuracy	100% (94.22 - 100)		100% (95.80 - 100)		97.80% (92.29 - 99.73)	

524

525 **Table S5.** Private school partners - health and safety modifications for in-person learning.

School_ID	School 01	School 02	School 03	School 04	School 05	School 06	School 07	School 08	School 09	School 10	School 11
Students	750	219	124	1300	261	1118	620	349	800	110	169
Staff	100	no data	33	410	65	250	150	85	200	18	39
Total # Tests	394	203	438	1761	212	4723	2066	3212	2772	53	519
Overall Test Positivity (%)	0.51	1.97	0.91	0.23	0.94	0.55	0.15	0.25	0.36	0	0.39
Date In-Person Instruction Resumed	2020-09-01	no data	2020-09-08	2020-09-07	2020-09-01	2020-09-02	2020-09-07	2020-08-28	2020-09-02	2020-10-16	2020-09-14
Student Testing Plan	Upon return from breaks, when there is an exposure on campus	no data	Upon return from breaks, as parents choose to utilize	Testing once a month for lower school students, twice monthly for middle school/high school students, special program for athletics	Asymptomatic, surveillance testing of roughly 1/2 the elementary students each week. All after breaks of a week or longer.	1/3 of the campus (students/staff) every week, test whole community after breaks such as Thanksgiving and Christmas	Testing in accordance with California Dept. of Public Health recommendations (frequency determined by County tier)	Testing all staff and students every week for December and January, reassess in late January for February plan	10% tested each month. Greater percentage following breaks. (Entire student body encouraged to test following breaks)	Asymptomatic testing - all students - once before returning from Winter Break in January future testing of asymptomatic students is TBD	Testing entire school community upon return from breaks and if there is a potential exposure on campus. Testing offered to students that may have been exposed, are

70

											participating in outside club cohorts, and/or who have been randomly selected each week (approximately 30 tests per week).
Staff Testing Plan	Every 2 weeks, as requested, also offered if exposure on campus	no data	Monthly, usually coincides with return from a break	Weekly	Every 2 weeks	1/3 of the campus (students/staff) every week, test whole community after breaks such as Thanksgiving and Christmas	Weekly	Testing all staff and students every week for December and January, reassess in late January for February plan	Weekly	Twice a month	Testing entire school community upon return from breaks and if there is a potential exposure. Testing staff every two weeks and as requested.
Instruction Model	50% of students on campus each day. Starting Mid-March we will bring all students back 4 days a week	no data	no data	In person, a/b cohort for MS and US. LS A/B on campus daily.	In person, full-day, students move to outdoor classrooms several times throughout each day. . Families can opt for virtual learning (approx 10%). Students can join virtual learning if in quarantine or isolation.	In person, students could opt for elearning but their is no hybrid option, approxiamately 135 e learning	Three of six grades on campus (50%); families have option to remain fully remote	1/3 of student body in person each day.	on campus is offered to all students, parents have the option to choose hybrid or 100% remote	We are offering a full day (9am-3pm) on-campus program daily for all students. 85% of students are on-campus for instruction; 15% have selected our at-home option. Teachers are teaching concurrent classes using hybrid Owls and Zoom to broadcast classes to at-home learners.	
Classroom Size & Location	Various indoor and outdoor options.	no data	no data	12-16 in a class depending on room size, LS, 12 per class. `	11-16 per class depending on room size	varies by division 12-20	Various indoor and outdoor options.		Various indoor and outdoor options.	varies from 9 to 14 stable groups, outside classroom	Various indoor and outdoor options

	Col1	Col2	Col3	Col4	Col5	Col6	Col7	Col8	Col9	Col10	Col11
											tents is primary location
Other Safety Procedures	Screening, masks, increased distance, air filters, improved HVAC filters, grab and go lunch, lower density in classrooms, outdoor performing arts	no data	no data	Utilized "Health and Safety FIRST" protocol for general safety (Face masks / Ill? Stay at home / Remove germs / Six feet apart / Temperature check). Also used Emocha health-screening app used to report symptoms.	physical distance, masks, symptom screening, ventilation, outdoor learning, staggered arrival, stable groups, modified on-campus movement (not all apply to preschool)	Health Screen, Mandatory maskes, increased distance seating, outdoor classrooms, no more than 45 at time in indoor classroom, CO2 sensors, fans, air filters, Daily disinfecting procedures. staggered drop off and pick up	Screening, masks, increased distance, air filters, improved HVAC filters, grab and go lunch, lower density in classrooms, outdoor performing arts	Screening, maks, increased distance, air filters, lower density classrooms	Screening, masks, increased distance, air filters, improved HVAC filters, grab and go lunch, lower density in classrooms, outdoor performing arts	staggered arrival and dismissal, morning screenings, masks for all, increased physcial distancing, outside instruction for the majority of the time, air purifiers, handwashing stations in each outdoor classroom	Screening, mandatory masks, increased distance, air filters, improved HVAC filters, increased hand washing stations, more outdoor classrooms, increased cleaning and sanitation
Face Covering Requirements	Masks required for everyone while on campus. Teachers are offered disposable surgical masks.	no data	no data	Required at all times for students and faculty. Staff may remove if in a private office.	Masks required at all times except eating for everyone ages 3 and up	Masks required, all ages, at all times except eating and naptime	no data	no data	no data	Required for all	Masks required at all times (except for lunch where students are socially distanced)
Minimum Spacing Between Desks	6 feet (1.8 m)	no data	no data	6 feet (1.8 m)	6 feet (1.8 m) for elementary students	4-6 feet (1.2-1.8 m)	no data	no data	no data	5-6 feet (1.5-1.8 m)	6 feet (1.8 m)
HVAC Modifications	UV-C disinfecting lamps on the supply end of HVAC	no data	no data	Upgraded HVAC air filters, portable air purifiers	Increased air filter to M13-grade, added UV	Portable HEPA systems	no data	no data	no data	Upgraded HVAC air filters, portable air purifiers	Upgraded air filtration systems to M13-grade, added portable HEPA systems and fans
Indoor/Outdoor instruction	no data	no data	no data	Indoor with max ventilation at all times.	Both indoor and outdoor, alternating throughout the day	CO2 monitors with mandatory outside time if >700 ppm. At least 15 minutes outdoor time per hour. All eating is outdoors.	no data	no data	no data	Fully functioning outdoor classroom tents with TV monitors, white boards, doc cam and battery power, indoor is permitted but	CO2 monitors with mandatory outside time; most classes are conducted outdoors for at least 50% time

											encouraged to be very little time
Cohort Size	no data	no data	no data	Currently 12	Each grade level (approx 25-30 students)	Elementary: classroom. Middle and High School: grade level	no data	no data	no data	9 to 14	Each grade level
Cleaning	Regular disinfecting of high touch areas throughout the day, nightly electrostatic disinfecting of entire campus	no data	no data	Circulating, 3x and after room use.	Day porter added to disinfenct surfaces in calssrooms while students are outside	Cleaning service, including electrostatic sanitization	no data	no data	no data	Daily janitorial service, recess PE/equipment sprayed with disinfectant after each use; teachers instructed to wipe down surfaces if rotating between classrooms	Regular disinfection of high touch surfaces; nightly disinfection; janitorial service daily
Symptom Screening	Yes - upon entry to campus using the SchoolPass wellness app	no data	no data	Yes - using Emocha	Yes - using ProCare app	Yes - Using commercial app. Checked at arrival	no data	no data	no data	Yes - parents and staff fill out screening app each morning	Yes - daily using in-house proprietary check-in system
Temperature Checks	Yes - through the SchoolPass app and again as they enter campus	no data	no data	Yes - part of Emocha and staff at gate	Yes - at arrival at school for all	Yes - checked at arrival to school	no data	no data	no data	Yes - checked at arrival gate	Yes - through daily health check-in. Students that have not yet checked in are screened prior to entering campus.
Result Notification for Positive Tests	Yes - by Phone call and email	no data	no data	Yes - by School Nurse	Yes - by school nurse/Pandemic Coordinator	Yes - By athletic trainer	no data	no data	no data	Yes - by Director of Operations	Yes - by Phone call and e-mail
Result Notification for Negative Tests	Yes - by email	no data	no data	No	No	No	no data	no data	no data	Yes - by Director of Operations	Yes - by E-mail
Contact Tracing, Isolation, & Quarantine	Conducted in partnership with the school nurse and San Diego County	no data	no data	Conducted by school nurse and team of support with Director of Security and Environmental Health and Safety	Condcted by school nurse/Head of School/Assistant Head of School	By athletic trainer according to CDC guidelines	no data	no data	no data	Conducted by Director of Operations, Head of School, Administrative Assistant	Conducted by Principal, who is the lead with all testing, result notification, contact tracing, isolation, and quarantine